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ABSTRACT 
The European Society for Medical Oncology (ESMO) consensus conference on testicular 
cancer was held on 3–5 November 2016 in Paris, France. The conference included a 
multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular 
cancer (34 panel members attended the conference; an additional two panel members [C.B. 
and K.-P.D.] participated in all preparatory work and subsequent manuscript development). 
The aim of the conference was to develop detailed recommendations on topics relating to 
testicular cancer that are not covered in detail in the current ESMO Clinical Practice 
Guidelines and where the available level of evidence is insufficient. The main topics 
identified for discussion related to: (1) diagnostic work-up and patient assessment; (2) stage I 
disease; (3) stage II–III disease; (4) post-chemotherapy surgery, salvage chemotherapy, 
salvage and desperation surgery and special topics; and (5) survivorship and follow-up 
schemes. The experts addressed questions relating to one of the five topics within five 
working groups. Relevant scientific literature was reviewed in advance. Recommendations 
were developed by the working groups and then presented to the entire panel. A consensus 
vote was obtained following whole-panel discussions, and the consensus recommendations 
were then further developed in post-meeting discussions in written form. This manuscript 
presents the results of the expert panel discussions, including the consensus recommendations 
and a summary of evidence supporting each recommendation. All participants approved the 
final manuscript. 
Word count: 228 (limit: 300 words) 
 
KEY WORDS: testicular germ cell cancer, consensus, diagnosis, treatment, quality of life, 
follow-up 
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KEY MESSAGES  
• This ESMO consensus conference manuscript on testicular germ cell cancer was 
compiled by a multidisciplinary panel of experts 
• It provides guidance on controversial issues surrounding the diagnosis, treatment and 
follow-up of early- and late-stage testicular cancer, and for rare clinical problems and 
survivorship issues 
• Recommendations are accompanied by relevant/available supporting evidence 
Character count: 398 (limit: 400, including spaces) 
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INTRODUCTION 
See Section 1 of supplementary text, available at Annals of Oncology online. 
 
METHODS 
On 3–5 November 2016, the European Society for Medical Oncology (ESMO) held a 
consensus conference in Paris, France, to discuss controversial issues relating to the 
diagnosis, treatment and follow-up of patients with testicular cancer that have not been 
addressed in the current Clinical Practice Guideline (CPG). The conference included a 
multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular germ 
cell cancer (TGCC) (34 panel members attended the conference; an additional 2 panel 
members [C.B. and K.-P.D.] participated in all preparatory work and subsequent manuscript 
development) and was chaired and co-chaired by F. Honecker and A. Horwich, respectively. 
All experts were allocated to one of five working groups. 
Each working group covered a specific subject area and was appointed a chair as follows: 
1. Diagnostic work-up and patient assessment (Chair: G. Cohn-Cedermark) 
2. Stage I disease (Chair: J. Aparicio) 
3. Stage II–III disease (Chair: K. Fizazi) 
4. Post-chemotherapy surgery, salvage chemotherapy, salvage and desperation surgery and 
special topics (Chair: J. Beyer) 
5. Survivorship and follow-up schemes (Chair: J. Oldenburg) 
Further details of methods can be found in Section 2 of the supplementary text, available at 
Annals of Oncology online. 
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RESULTS 
Diagnostic work-up and patient assessment 
1. Is there a role for targeted screening?  
Incidence of testicular cancer by ethnic origin. 
The incidence of testicular cancer varies by ethnic origin, with the highest rates reported in 
developed countries and lowest in developing countries. The highest incidence rates of 
testicular cancer are in Norway (11.8 per 100 000) and the lowest are in India (0.5 per 
100 000) and Thailand (0.4 per 100 000) [1]. The increase in incidence rates of testicular 
cancer in both developed and developing countries is due to a birth cohort effect [2]. In high-
incidence Scandinavian countries, the increase has levelled off. The risk of testicular cancer 
in Swedish-born sons of low-risk Finnish immigrant parents is no longer different from that 
in native Swedes, which implies a strong environmental influence [3]. 
Risk factors of testicular cancer. 
Individual risk factors for testicular cancer include cryptorchidism (relative risk [RR] ≥3.18), 
hypospadias (RR 2.41), inguinal hernia (RR 1.37) and other birth-related factors of a lower 
risk [4, 5]. Among endocrine disruption chemicals, organochlorine compounds have been 
associated with a risk of developing testicular cancer [5]. Cryptorchidism is associated with a 
higher risk for ipsilateral testicular cancer (RR 6.33) than contralateral testicular cancer 
(RR 1.74) [6]; however, men with a family history of cryptorchidism or hypospadias have no 
increased risk of testicular cancer [7]. 
Approximately 5% of men with testicular cancer develop contralateral testicular cancer, of 
which one-third are synchronous tumours and two-thirds are metachronous tumours [8]. 
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Compared with the incidence rates of a first testicular cancer, the RR for developing a second 
testicular cancer is 29 after seminoma and 13 after non-seminoma [9].  
Familial risk is more relevant for testicular cancer than in the majority of other cancers. The 
risk is significantly higher if the affected family member is a brother (RR 6.94) rather than 
the father (RR 3.90), which is likely due to a recessive genetic or birth cohort-related effect 
[10]. About 1.8% of patients have a parent or a sibling also diagnosed with testicular cancer 
[10].  
According to a Nordic study on testicular cancer, the standardised incidence risk ratios for 
seminoma in brothers (4.2) had no major difference from the risk of all testicular cancer 
subtypes in brothers (4.1). However, fraternal risk for non-seminomatous germ cell tumours 
(NSGCTs) (10) and mixed germ cell tumours (17) were higher compared with all testicular 
cancer subtypes (11). In the same study, high familial risks were observed for men who had 
two or more affected relatives (17) or if a twin brother was diagnosed with testicular cancer 
(20). The absolute population risk of testicular cancer in the Nordic countries was 0.6% by 
the age of 79 years. This increased to 1.2%, 2.3%, 10.3% and 56.2% if a father, brother, >2 
relatives or a twin brother was diagnosed, respectively [11]. 
Genetic predisposition for testicular cancer. 
Over 20 single nucleotide polymorphisms (SNPs) have been associated with the risk of 
testicular cancer [12, 13]. Polygenic risk scores have been used to show that men in the top 
1% of this genetic risk score have a 9-fold increased risk of testicular cancer compared with 
the population median [14]. Collectively, the SNPs identified to-date explain around 19% of 
the empirical fraternal familial risk [14]. Based on the Swedish Family-Cancer Database [15], 
population-based heritability of testicular cancer is estimated at 49%. 
Targeted screening for testicular cancer. 
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Due to the shortage of randomised, controlled trials on the benefits of screening for testicular 
cancer, no screening recommendations can be given [16]. However, the above data show that 
it is possible to define men who have a substantially increased risk for the development of a 
testicular cancer based on family history, genetic predisposition (polygenic risk score), 
individual history of testicular cancer or cryptorchidism, or a combination of these factors. 
Screening after testicular cancer diagnosis is discussed later in this article. 
Recommendation 1.1: Targeted screening should be advised for either a twin brother or those 
with two close family members with a history of germ cell tumours. 
Level of evidence: III-V 
Strength of recommendation: A-C  
Level of consensus: 97% (32) yes, 3% (1) no (33 voters) 
Recommendation 1.2: Since elevated testicular cancer risk exists for brothers and fathers, the 
patient should be encouraged to inform them of the need for self-examination. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 100% yes (33 voters) 
 
2. Pathology assessments 
Misdiagnosis and overtreatment of testicular tumours. 
Despite their relative rarity, testicular tumours are regarded as one of the most diverse areas 
of human pathology. They are further complicated by post-chemotherapy changes that can be 
seen after treatment. Even pathologists with an interest in uro-pathology may see relatively 
few tumours in a year, and so subtypes are prone to misdiagnosis and potential overtreatment.  
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The potential for misdiagnosis of stage and type of testicular tumour has been demonstrated 
in multiple articles and the dangers of subsequent mistreatment are substantial [17-21]. Based 
on these findings, The National Institute for Health and Clinical Excellence (NICE) guidance 
(Improving Outcomes in Urological Cancer [www.nice.org.uk]) recommended the 
establishment of a supra-network of specialised testicular cancer uro-pathologists, serving a 
population base of 2–4 million and managing 50–100 new patients per year. Central review 
of tumours by a specialist testicular pathologist is mandatory [22]. Recently, a survey of 
expert and non-expert uro-pathologists in Europe was conducted [23], which showed 
variability in reporting stage, rete testis invasion and other potentially prognostic parameters. 
If pathology is not centralised but pooled from reports, this could impact studies of testicular 
risk factors for recurrence.  
Typing of testicular tumours for oncology assessment. 
Testicular tumours should be typed in line with the World Health Organization (WHO) 2016 
classification [24]. This allows for a modified nomenclature and a more patho-genetic 
approach to TGCCs, the final aim being to avoid overtreatment of patients with negligible 
risk of spread. The new name for pre-neoplastic lesions of TGCCs has been agreed upon as 
germ cell neoplasia in situ (GCNIS). GCNIS were formerly named carcinoma in situ or 
testicular intraepithelial neoplasia [25]. Prepubertal type teratomas are known to exist in 
adults, and may require less surveillance [26]. For optimal management of testicular tumours, 
whenever possible, oncologists should request a review of each case by an expert testicular 
pathologist who sees a minimum of 30 cases per year. 
Recommendation 2.1: The pathology of testicular tumours should be assessed, or at least 
reviewed, by a specialist testicular pathologist who sees a minimum of 30 cases per year. 
Level of evidence: III 
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Strength of recommendation: A 
Level of consensus: 87.1% (27) yes, 12.9% (4) abstain (31 voters) 
Recommendation 2.2: The WHO 2016 classification should be routinely adopted for 
testicular pathology assessment. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: 74.2% (23) yes, 25.8% (8) abstain (31 voters) 
Staging in testicular cancer tumours. 
The 7th Tumour Node and Metastases (TNM) classification does not adequately supply all 
information required by many oncologists for patient treatment [27], as rete testis invasion 
and tumour size are not included in its assessments. Recently, both the American Joint 
Committee on Cancer (AJCC) 8th TNM version [28] and the Union for International Cancer 
Control (UICC) 8th edition [29] have been published, and the AJCC version has addressed 
some of these issues. For seminoma, T1 has been subdivided into pT1a and 1b for tumours 
< versus ≥3 cm. Soft tissue and epididymal invasion have been redefined as pT2. Rete testis 
invasion remains as T1 disease. Unfortunately, these changes have not been adopted by the 
UICC, which may lead to some confusion in prospective staging. At present, the AJCC 
provides a better staging method and has been endorsed by the International Society of 
Urological Pathology [30]. [Note to Ann Oncol: We have used UK spelling when defining the 
abbreviation TNM (tumour instead of tumor) to align with journal style. Please confirm you 
agree] 
Minimum pathological datasets for oncological assessment of relapse risk in testicular 
cancer. 
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Guidelines on pathological datasets are available from The College of American Pathologists, 
The Royal College of Pathologists [22] and The Royal College of Pathologists of Australia. 
These guidelines have been combined to form an international dataset on minimum 
standards, which has been published by the International Collaboration on Cancer Reporting 
(ICCR) [31]. It is recommended that testicular pathologists should use one of these datasets 
for guidance in reporting. 
Recommendation 2.3: National or international minimum dataset guidelines should be used 
by testicular pathologists. The dataset for pathology reporting to minimum standards should 
be according to the ICCR minimum dataset. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: 100% yes (31 voters) 
 
3. Should contralateral biopsy be performed?  
Contralateral biopsies in testicular cancer. 
Early detection of TGCC is possible by diagnosing GCNIS, the pre-invasive stage of TGCC 
[32, 33]. The current theory of TGCC pathogenesis asserts that GCNIS cells arise from 
embryonic germ cells that are present in a dormant state in the juvenile testicle; after 
adolescence, it is possible for GCNIS to progress to invasive TGCC at any time [5]. The 
current understanding of the pathogenesis of TGCC provides clinically useful knowledge 
because it suggests: (1) all TGCCs develop from GCNIS (i.e. without previous GCNIS, there 
can be no invasive TGCC); (2) there is no de novo development of GCNIS in adulthood; (3) 
GCNIS is present many years before the clinical manifestation of TGCC; (4) GCNIS can be 
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detected patho-histologically; (5) as it is usually distributed over wide areas, GCNIS can be 
detected by surgical biopsy [34, 35]. 
Surgical technique. 
Evidence suggests that performing two-site testicular biopsies provides an increased 
sensitivity of 18% compared with single-site biopsy [34, 36]. Surgical complications have 
been reported to occur in 2%–3% of patients, most of which can be managed conservatively 
[37]. Currently available data suggest that screening for GCNIS by needle biopsy or semen 
examination yields inferior results to two-site surgical testicular biopsy [38, 39]. 
Histological technique. 
Histological detection of GCNIS cells can usually be achieved using conventional 
haematoxylin and eosin staining. In unresolved cases, supplementary immunohistochemical 
staining can be performed with immunohistochemistry for placental alkaline phosphatase, 
D2–40 or OCT3/4 [40, 41]. Spermatogenesis should also be assessed morphologically. 
Clinical data. 
In central and northern European countries, GCNIS was found to be present in the 
contralateral testis of 4.4%–8.1% of patients with TGCC [34, 36, 42-44]. Major risk factors 
associated with contralateral GCNIS in patients with unilateral TGCC include testicular 
atrophy, younger age (<40 years), testicular microlithiasis and infertility [45]; the GCNIS rate 
was 18% in patients aged <40 years with testicular atrophy (≤12 mL). The prevalence of 
contralateral GCNIS appears to correspond to the reported 2%–4% frequency of bilateral 
testicular tumours [8, 46, 47]. In patients with extragonadal TGCCs, testicular biopsies have 
revealed the presence of GCNIS in approximately 31% of these patients, with the risk being 
higher in retroperitoneal primaries [48].  
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The rate of false-negative biopsies (i.e. patients who developed TGCC subsequent to having 
negative biopsy results) has been reported as 0.5%–2% [42, 46]. However, diagnostic failure 
is likely related to methodological inadequacies, such as use of single-site rather than two-site 
biopsies and lack of immunohistological examination, or the timing of biopsy, e.g. after 
chemotherapy. Nevertheless, the possibility of a false-negative biopsy must be taken into 
consideration as, contrary to former opinion, GCNIS cells are not homogeneously distributed 
over the testis [42, 49]. 
General considerations of the usefulness of contralateral biopsies. 
There is currently no consensus amongst experts of TGCC treatment as to whether a 
contralateral biopsy should be performed [50]. There are no data to show that it can provide 
an additional survival advantage [51]. However, performing a contralateral biopsy may 
confer additional benefits to the patient. Firstly, in those with a ‘positive’ biopsy result, the 
potential early diagnosis of a second testicular cancer allows for prospective testis-preserving 
treatment; importantly, this not only minimises the aggressiveness of treatment required, 
including reduced exposure to treatment-related toxicity, but also reduces the extent of 
follow-up clinical and radiological examinations required compared with treatment and 
follow-up for a more advanced second tumour. Secondly, patients with a ‘negative’ biopsy 
result benefit from the knowledge that their risk of developing a contralateral tumour is very 
low, which also translates into a reduced scrotal follow-up schedule. Thirdly, the biopsy can 
provide valuable information regarding the fertility potential of the patient.  
The risk of damage to the contralateral testis because of the surgical biopsy procedure has 
been shown to be minimal [37]. Furthermore, concerns that GCNIS treatment may potentially 
harm fertility may be irrelevant for many patients, as a large proportion of testes with GCNIS 
are primarily associated with poor spermatogenesis [52]. 
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Overall, it seems reasonable to discuss the value of performing contralateral biopsies with 
patients who have high-risk factors for a second TGCC (i.e. those aged <40 years with a 
small atrophic testis and those with testicular microlithiasis upon scrotal sonography). 
Recommendation 3.1: Biopsies of the contralateral testis at the time of orchiectomy should 
be discussed with, and recommended to, high-risk patients (i.e. those aged <40 years with a 
small atrophic testis and/or microlithiasis). 
Level of evidence: III  
Strength of recommendation: A 
Level of consensus: 93.8% (30) yes, 3.1% (1) no, 3.1% (1) abstain (32 voters) 
 
4. Imaging techniques 
Diagnosis of testicular cancer. 
Testicular ultrasound (US) should be performed using a high frequency (>10MHz) probe 
with colour Doppler assessment to confirm the presence of a testicular mass [53], prior to 
orchiectomy and exploration of the contralateral testis. In addition to confirming the presence 
of an intra-testicular mass, US can be used to evaluate the contralateral testis for the presence 
of synchronous tumours and microcalcifications, and to measure the testicular volume. US 
can also be used to detect an occult testicular mass in patients presenting with metastatic 
disease. Contrast-enhanced US of the testis is a technique that is particularly helpful in 
identifying and characterising small intra-testicular masses of <1 cm [54-58].  
Although scrotal magnetic resonance imaging (MRI) is good at identifying and characterising 
testicular tumours [59], currently its role is to help distinguish between an intra- and extra-
testicular mass when this cannot be confirmed clinically or with US [60]. 
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Recommendation 4.1: Testicular US using high frequency (>10MHz) probe with colour 
Doppler assessment should be performed to confirm the presence of a testicular mass prior to 
orchiectomy or possible exploration of the contralateral testis. 
Level of evidence: V 
Strength of recommendation: A 
Level of consensus: No vote obtained 
Staging of testicular cancer. 
Computed tomography (CT) of the thorax, abdomen and pelvis is the imaging modality of 
choice in the staging of testicular tumours. In order to optimise the assessment of the 
retroperitoneum and to identify metastases, CT should be performed with intravenous 
contrast media and oral opacification of the bowel with water or positive contrast media. The 
size of any metastases should preferably be described in three dimensions, and at least by the 
maximum axial diameter. 
Is there a role for PET-CT or MRI versus CT in testicular cancer? 
Brain MRI (or contrast-enhanced CT if MRI is contraindicated) is required in patients with 
central nervous system symptoms or those presenting with widespread metastatic disease 
and/or high levels of beta-human chorionic gonadotropin (β-hCG) [61].  
Fluorodeoxyglucose-positron emission tomography (FDG-PET) demonstrates no advantage 
over CT as an imaging modality in patients with clinical stage I disease, due to its inability to 
reliably identify disease activity in sub-centimetre lymph nodes [62]. However, FDG-PET 
may have a role in resolving equivocal CT findings, as the slightly higher sensitivity with 
FDG-PET may be useful in evaluating borderline lymph nodes [63]. Alternatively, targeted 
interval CT provides an option to assess growth of the borderline nodes using a lower dose of 
radiation. Importantly, clinicians must be aware of the limitations of FDG-PET if it is used as 
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a problem-solving tool to resolve CT findings, for example, inflammatory lesions can also be 
FDG-avid on PET. 
Currently, MRI is used when CT is inconclusive or contraindicated because of an allergy to 
the contrast media. MRI is the modality of choice for suspected bone marrow or central 
nervous system involvement and may be a useful problem-solving tool in difficult cases. 
Recommendation 4.2: Contrast-enhanced CT is recommended in all patients for staging prior 
to orchiectomy. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: No vote obtained 
Recommendation 4.3: MRI may be helpful for characterisation of equivocal CT findings 
(e.g. in liver, bone, brain). 
Level of evidence: IV 
Strength of recommendation: A 
Level of consensus: No vote obtained 
Recommendation 4.4: Brain MRI (or contrast-enhanced CT if MRI is contraindicated) is 
recommended in patients with symptoms or those with widespread metastatic disease and 
high levels of β-hCG. 
Level of evidence: IV 
Strength of recommendation: A 
Level of consensus: No vote obtained 
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Recommendation 4.5: MRI is not routinely recommended in all patients for staging of the 
retroperitoneum. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 94.1% (32) yes, 5.9% (2) abstain (34 voters) 
Recommendation 4.6: PET-CT is not routinely recommended in all patients for staging. 
Level of evidence: I 
Strength of recommendation: B 
Level of consensus: 94.1% (32) yes, 5.9% (2) abstain (34 voters) 
Recommendation 4.7: PET-CT is not considered to be useful for staging in the case of 
negative contrast-enhanced CT and marker-positive disease. 
Level of evidence: V 
Strength of recommendation: C 
Level of consensus: 88.2% (30) yes, 5.9% (2) no, 5.9% (2) abstain (34 voters) 
[Note to Ann Oncol: We bolded the term ‘not’ in the above recommendations to highlight 
recommendations against a particular practice - please can we retain this bolding in final 
publication] 
Recommendation 4.8: In marker-negative disease, if contrast-enhanced CT shows equivocal 
lymph nodes, repeated staging with contrast-enhanced CT after 6–8 weeks is recommended. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 97.1% (33) yes, 2.9% (1) abstain (34 voters) 
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Recommendation 4.9: In marker-negative disease, if contrast-enhanced CT shows equivocal 
lymph nodes, repeated staging with PET-CT is not recommended. 
Level of evidence: V 
Strength of evidence: C 
Level of consensus: 88.2% (30) yes, 5.9% (2) no, 5.9% (2) abstain (34 voters) 
[Note to Ann Oncol: We bolded the term ‘not’ above to highlight that this is a 
recommendation against a particular practice - please can we retain this bolding in final 
publication] 
Post-treatment assessment of testicular cancer. 
In the post-treatment assessment and follow-up of patients, CT is the primary imaging 
technique used. However, due to the radiation risk associated with CT, MRI may be used as 
an alternative in assessing the abdomen and pelvis. MRI is comparable to CT in the detection 
of retroperitoneal nodal metastases when interpreted by an experienced radiologist [64]. The 
detection of lymph nodes is enhanced by the addition of diffusion-weighted imaging to 
conventional MRI sequences (i.e. T1- and T2-weighted images) [65]. The Swedish-
Norwegian Testicular Cancer Project (SWENOTECA) has used MRI extensively during 
follow-up instead of CT and has recorded excellent data for survival and tumour stage at 
disease recurrence [66]. Results are awaited from a multicentre, randomised, prospective 
study (TRISST) in the UK, which is using MRI and CT to evaluate the abdomen in patients 
with stage I seminoma managed by surveillance [67].  
Recommendation 4.10: An MRI can be recommended for follow-up of the retroperitoneum, 
if standard protocols are used and the results are reported by an experienced radiologist. 
Level of evidence: III 
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Strength of recommendation: A 
Level of consensus: 85.3% (29) yes, 2.9% (1) no, 11.8% (4) abstain (34 voters) 
Residual mass evaluation: Imaging is used to assess residual disease and may allow for 
selection of patients who could potentially benefit from further treatment. In patients with 
large volume residual disease, CT, MRI and FDG-PET may be useful in surgical planning. 
Multiplanar reformat and identification of critical structures with CT or MRI could direct the 
surgical approach required. In addition, the use of FDG-PET may facilitate tailoring of 
surgery to metabolically active sites of disease. The chosen imaging modality performed and 
any subsequent interpretation depends on whether the lesion is a seminoma or NSGCT.  
FDG-PET is a valuable tool for clinical decision-making in post-chemotherapy seminoma 
residual masses [68-73]. In residual masses >3 cm, an appropriately timed PET is more 
reliable than CT in predicting necrosis/fibrosis or viable tumour, and thus able to spare 
patients unnecessary additional treatment such as surgery or radiation (sensitivity in lesions 
>3 cm is 88% and negative predictive value is 96%) [71]. The limitations of FDG-PET 
include false-positive scans due to inflammatory and granulomatous tissue and performing 
the PET too soon after chemotherapy. In such circumstances, a subsequent follow-up PET 
may show a negative PET result or decreasing FDG uptake. False-negative PET results may 
be caused by limited resolution as a result of tiny (5 mm) residual disease or by inadequate 
timing. 
In NSGCT, CT can facilitate assessment of post-treatment residual masses by depicting 
changes in morphology [74]. As teratoma has variable, low or no FDG uptake, FDG-PET 
cannot be used to distinguish this from fibrosis or necrosis [75-77]; thus FDG-PET is unable 
to assist in the decision as to whether the response requires surgery or not. 
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Recommendation 4.11: FDG-PET-CT may be helpful to assess residual masses >3 cm in 
patients with seminoma if performed at least 8 weeks after the end of chemotherapy. If the 
results are negative, FDG-PET-CT has a very high negative predictive value. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: No vote obtained 
Recurrent testicular cancer: FDG-PET may also have a role in the detection of recurrent 
disease. In patients with raised tumour markers and negative imaging findings (including 
negative FDG-PET), follow-up with a repeat FDG-PET is the most sensitive imaging 
modality to identify the site of relapse [63, 76]. 
Recommendation 4.12: Repeat FDG-PET-CT may be useful in patients with marker-positive 
relapse and a negative contrast-enhanced CT result. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: No vote obtained 
Recommendation 4.13: The follow-up contrast-enhanced CT should be of the abdomen only. 
Level of evidence: IV 
Strength of recommendation: C 
Level of consensus: 78.8% (26) yes, 9.1% (3) no, 12.1% (4) abstain (33 voters) 
 
5. Diagnostic tools 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
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Stage I testicular cancer  
6. Are there risk factors validated and/or accepted for seminoma? 
In the absence of adjuvant treatment, approximately 15%–20% of patients with stage I 
testicular seminoma will develop recurrence. Most of these recurrences arise in 
retroperitoneal lymph nodes [78-80]. In contrast to non-seminoma, risk factors to guide 
adjuvant treatment in patients with stage I seminoma are not well established. The two main 
risk factors that have been studied are primary tumour size and stromal (but not pagetoid) 
invasion of the rete testis by seminoma. A nomogram produced by Warde et al. suggested a 
12% risk of recurrence in the absence of both risk factors, a 16% risk of recurrence in the 
presence of either of the two risk factors and a 32% risk of recurrence in the presence of both 
risk factors [81]. However, subsequent studies have shown more heterogeneous results. In a 
prognostic model based on data from 685 stage I seminoma patients, Chung et al. failed to 
validate the nomogram and simply identified tumour size as a risk factor for recurrence 
without any clear, size-related cut-off [82]. In contrast, a Japanese study of 425 patients 
undergoing orchiectomy for stage I testicular seminoma concluded that rete testis 
involvement is a risk factor for recurrence with or without adjuvant treatment [83]. A large 
retrospective Danish analysis concluded that tumour size was a significant factor for relapse, 
together with either invasion of epididymis or vascular invasion [78]. SWENOTECA 
describes both primary tumour size and rete testis involvement as risk factors for recurrence 
[79]. The Spanish Germ Cell Cancer Group (SGCCG) has published three consecutive 
studies on the management of stage I seminoma with different risk-adapted treatment 
strategies [84-86]. The nomogram developed by the SGCCG takes into account both primary 
tumour size (as a continuous variable) and stromal involvement of the rete testis [87]. For 
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objective evaluation of the individual risk of recurrence, the SGCCG nomogram may be the 
most useful. 
Recommendation 6.1: Both rete testis stromal invasion and primary tumour size should be 
considered as risk factors for relapse in stage I seminoma.  
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 91% (29) yes, 9% (3) abstain (32 voters)  
Recommendation 6.2: In patients with seminoma, in the case of primary tumour size, there is 
no definitive cut-off value; however, larger tumours appear to confer higher risk of 
recurrence as a continuous variable. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 94% (30) yes, 6% (2) abstain (32 voters)  
Recommendation 6.3: Patients with seminoma without any identified risk factor (e.g. no rete 
testis involvement and small tumour size) have a very low risk of recurrence. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 75% (24) yes, 25% (8) abstain (32 voters)  
 
7. Are there risk factors validated and/or accepted for non-seminoma?  
Active surveillance studies have identified the presence of vascular invasion, the presence of 
undifferentiated cells and the absence of yolk sac elements as risk factors for relapse in 
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patients with non-seminoma [88]. In a cohort of 373 patients, the presence of no, one, two or 
three risk factors was associated with 2-year relapse rates of 0%, 16%, 21% and 47%, 
respectively. In the case of isolated lymphatic or venous invasion with no other risk factors, 
the 2-year relapse rate was 41% and 35%, respectively [88]. In recent studies, the prognostic 
significance of the presence of lymphovascular invasion (LVI) has been validated. Evaluating 
1139 clinical stage I patients under active surveillance, Kollmannsberger et al. described 
relapse rates of 44% and 14% in patients with and without LVI [80]. Additionally, the 
median time to relapse was different between patients with and without LVI (4.0 versus 
8.0 months). In a large Danish study, the relapse rate after orchiectomy alone was 30.6% at 
5 years. Presence of vascular invasion together with embryonal carcinoma and rete testis 
invasion in the testicular primary identified a group with a relapse risk of 50%. Without risk 
factors, the relapse risk was 12% [89]. 
Retrospective studies based on the patho-histology of resected lymph nodes following 
retroperitoneal lymph node dissection (RPLND) in clinical stage I non-seminoma have 
identified the presence of vascular invasion, the percentage of embryonal carcinoma (EC) and 
the presence of infiltration of the tunica albuginea as prognostic risk factors associated with 
pathological stage II disease [90]. Combining the percentage of EC with the presence or 
absence of vascular invasion enabled correct prediction of final pathological stage for 88% of 
clinical stage I patients. For patients with less than 45% EC and no vascular invasion, 
pathological stage I disease was correctly identified in 91.5% of patients; in the case of 
>80% EC and the presence of vascular invasion, pathological stage II was correctly predicted 
in 88% of patients [90].  
A recent retrospective study on 226 clinical stage I non-seminoma patients has validated the 
clinical risk factors mentioned above [91]. NSGCT patients were stratified according to 
predominance of EC and LVI, using a risk factor (RF) scoring system with the scale RF0, 
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RF1 and RF2. Relapse rates and median time-to-relapse were 25% and 8.5 months, 41% and 
6.8 months, and 78% and 3.8 months for RF0, RF1 and RF2, respectively. NSGCT patients 
grouped by a risk score system based on EC and LVI provided three groups of patients with 
distinct patterns of relapse [91]. 
Recommendation 7.1: In patients with non-seminoma, LVI is the key risk factor indicating 
disease relapse. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 100% (32) yes (32 voters)  
Recommendation 7.2: In patients with non-seminoma, a combination of LVI and 
predominance of EC appears to be associated with an even higher rate of stage II progression 
or relapse versus LVI alone.  
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 94% (30) yes, 6% (2) abstain (32 voters)  
Recommendation 7.3: Prospective collection of data on both markers (LVI and EC) is 
warranted.  
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 100% (32) yes (32 voters)  
 
8. Who should be offered adjuvant chemotherapy?  
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Seminoma. 
In clinical stage I seminoma, several studies have found a low risk of relapse (5%) in 
patients without risk factors [86, 87, 92]. In these patients, adjuvant chemotherapy will 
therefore result in over-treatment in approximately 95% of cases. In patients with a higher 
risk of relapse, adjuvant chemotherapy remains an option. Adjuvant carboplatin reduces the 
risk of relapse by about 60% [92], which provides a number-needed-to-treat (NNT) value in 
the range of 15–20 to prevent one relapse. 
Recommendation 8.1: Patients with seminoma and a low risk of relapse should not be 
offered adjuvant chemotherapy. 
Level of evidence: III 
Strength of recommendation: C 
Level of consensus: 91% (30) yes, 6% (2) no, 3% (1) abstain (33 voters)  
Recommendation 8.2: In patients with seminoma and a higher risk of relapse, surveillance or 
adjuvant carboplatin are options.  
Level of evidence: III 
Strength of recommendation: C 
Level of consensus: 91% (30) yes, 6% (2) no, 3% (1) abstain (33 voters) 
Recommendation 8.3: In patients with seminoma, patient autonomy should be taken into 
account following thorough provision of information regarding the pros and cons of the 
alternative treatment strategies.  
Level of evidence: III 
Strength of recommendation: C 
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Level of consensus: 91% (30) yes, 6% (2) no, 3% (1) abstain (33 voters) 
Non-seminoma. 
LVI is the major validated risk factor in stage I non-seminoma. In patients with LVI, the risk 
of relapse without adjuvant therapy is approximately 50% [93-96]. Salvage treatment 
generally consists of three to four courses of chemotherapy and possibly RPLND, which 
results in established patterns of side effects and late toxicity [97]. Adjuvant chemotherapy in 
the form of a single cycle of bleomycin/etoposide/cisplatin (BEP) will reduce the risk of 
relapse by over 90% [98]. As a consequence, adjuvant chemotherapy will spare 
approximately 50% of patients from salvage chemotherapy at the cost of 50% of patients 
unnecessarily receiving one course of BEP. This provides an NNT of 2.0–2.5 to avoid one 
relapse. In low-risk patients (LVI-negative), the relapse risk of 15% is reduced by 90%–95% 
following a single cycle of adjuvant BEP [98]. 
Recommendation 8.4: In patients with high-risk non-seminoma, adjuvant chemotherapy with 
one cycle of BEP is recommended if the patient is considered eligible for such treatment. 
Surveillance may be an alternative to adjuvant chemotherapy. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 72% (23) yes, 25% (8) no, 3% (1) abstain (32 voters)  
Recommendation 8.5: In patients with high-risk non-seminoma, patient autonomy should be 
taken into account following the provision of thorough information regarding the pros and 
cons of alternative management strategies. 
Level of evidence: III 
Strength of recommendation: B 
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Level of consensus: 72% (23) yes, 25% (8) no, 3% (1) abstain (32 voters) 
Recommendation 8.6: In patients with low-risk non-seminoma who are eligible for adjuvant 
chemotherapy, surveillance is recommended. Adjuvant chemotherapy may be an alternative 
to surveillance.  
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 97% (32) yes, 3% (1) abstain (33 voters)  
Recommendation 8.7: In patients with low-risk non-seminoma, patient autonomy should be 
taken into account following the provision of thorough information regarding the pros and 
cons of the alternative management strategies. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 97% (32) yes, 3% (1) abstain (33 voters) 
 
9. Should adjuvant chemotherapy be limited to one course of chemotherapy? 
Seminoma. 
In stage I seminoma, one course of adjuvant carboplatin has been compared with adjuvant 
radiotherapy in the large randomised Medical Research Council (MRC) TE19/European 
Organisation for Research and Treatment of Cancer (EORTC) 30982 trial [99]. In an 
unselected population, the relapse rate of 5.1% after one course of adjuvant carboplatin was 
comparable to that for adjuvant radiotherapy (4.1%). Some studies have used two courses of 
adjuvant carboplatin either dosed at area under the curve (AUC) 6–7 or at a fixed dose of 
400 mg/m2, with a reported relapse rate of 3%–4%, even in patients with risk factors [84-86, 
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100]. Two courses of adjuvant carboplatin are likely to be more effective than one course, but 
this has never been tested in a head-to-head study. Adjuvant carboplatin has only a modest 
effect in reducing the risk of relapse, and even with two courses of carboplatin, the risk of 
relapse is reduced from 15%–20% to 3%–4% [97]. Thus, there is a need to explore more 
efficient adjuvant therapies in patients with risk factors. 
Recommendation 9.1: One course of carboplatin AUC 7 is the standard adjuvant 
chemotherapy in stage I seminoma. 
Level of evidence: I 
Strength of recommendation: B 
Level of consensus: 97% (30) yes, 3% (1) abstain (31 voters) 
Non-seminoma. 
The first large series on the use of adjuvant chemotherapy in clinical stage I non-seminoma 
was published in 1996 and used two courses of BEP chemotherapy [101]. Since then, two 
courses of BEP have been the standard adjuvant treatment in clinical stage I non-seminoma. 
The first large studies using one course of BEP for non-seminoma patients were published in 
2008 and 2009 [94, 102]. In 2015, a large study with mature follow-up on 517 patients 
treated with one course of adjuvant BEP was published. With a median follow-up of 
7.9 years, no relapses beyond 3.3 years were detected, and a reduction in relapses of over 
90% was reported [79].  
Recommendation 9.2: One course of adjuvant BEP is the standard adjuvant chemotherapy in 
stage I non-seminoma.  
Level of evidence: III 
Strength of recommendation: B 
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Level of consensus: 97% (30) yes, 3% (1) abstain (31 voters) 
 
10. What is the optimal treatment of relapse after adjuvant chemotherapy? 
Seminoma. 
Treatment of relapse after adjuvant chemotherapy should be standard treatment according to 
the prognostic classification for metastatic disease [92, 103]. 
Recommendation 10.1: In patients with seminoma, treatment of relapse after adjuvant 
chemotherapy should be standard treatment according to the prognostic classification for 
metastatic disease. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 93% (28) yes, 7% (2) abstain (30 voters) 
Non-seminoma. 
Treatment of relapse after adjuvant chemotherapy should be standard treatment of metastatic 
disease, as defined by the international prognostic classification. Patients with localised 
abdominal and marker-negative relapse often show teratoma upon resection, and RPLND 
should be chosen as primary salvage treatment. This strategy has proven efficient and yields a 
100% cause-specific survival rate [98].  
Recommendation 10.2: In patients with non-seminoma, treatment of relapse after adjuvant 
chemotherapy should be standard chemotherapy for metastatic disease. 
Level of evidence: III 
Strength of recommendation: B 
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Level of consensus: 90% (28) yes, 10% (3) abstain (31 voters)  
Recommendation 10.3: In patients with non-seminoma with localised abdominal and 
marker-negative relapse, nerve-sparing (NS)-RPLND is the preferred option for primary 
salvage treatment. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 90% (28) yes, 10% (3) abstain (31 voters) 
 
11. Other treatment alternatives for stage I disease: is there a role for RPLND?  
RPLND is neither recommended nor performed as standard treatment for stage I testicular 
cancer [61]. However, it represents an alternative to active surveillance or adjuvant 
chemotherapy in clinical stage I non-seminoma patients who are not eligible for or not 
willing to accept one of the above mentioned therapeutic options. If conducted, RPLND 
needs to be done at tertiary referral centres with high levels of experience (i.e. ≥20 cases per 
year) [61, 104]. Furthermore, RPLND should preferably be performed as an open, nerve-
sparing procedure. RPLND might be conducted laparoscopically; however, a higher level of 
experience is needed for this procedure than for open RPLND [105].  
Primary nerve-sparing RPLND should be discussed in patients with pure teratoma and with 
risk factors associated with occult retroperitoneal lymph node metastases [106]. The chance 
of detecting lymph node metastases by nerve-sparing RPLND is in the range 16.7%–20% 
[106]. The presence of scars and/or calcifications in the non-tumour bearing testicular 
parenchyma or the presence of microscopic non-teratomatous germ cell tumour elements 
have been shown to be associated with higher risk [107]. The majority of metastases harbour 
chemorefractory teratoma cells [108]; therefore, RPLND seems to be the treatment of choice 
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in these cases. We recommend performing serial sections of the orchiectomy specimen in 
men with pure teratoma.  
Primary nerve-sparing RPLND may also be discussed among patients with clinical stage I 
teratoma with malignant somatic transformation. In a recent report, Giannatempo et al. 
demonstrated that, of 28 stage I patients who underwent primary RPLND, 35.7% harboured 
viable tumour cells in the resected lymph node samples [109].  
Recommendation 11.1: RPLND is an alternative treatment option to active surveillance or 
adjuvant chemotherapy in patients with stage I non-seminoma who are not eligible for or not 
willing to accept one of the above mentioned therapeutic options.  
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 90% (28) yes, 6% (2) no, 3% (1) abstain (31 voters)  
Recommendation 11.2: RPLND is the standard treatment in patients with clinical stage I 
pure teratoma and risk factors for occult retroperitoneal disease. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 62% (20) yes, 16% (5) no, 22% (7) abstain (32 voters)  
Recommendation 11.3: RPLND is the standard treatment in patients with clinical stage I 
teratoma with malignant somatic transformation. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 90% (28) yes, 3% (1) no, 6% (2) abstain (31 voters)  
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12. Is there still a role for radiotherapy in clinical stage I testicular seminoma? 
Adjuvant radiotherapy was the standard adjuvant treatment in clinical stage I seminoma 
patients for several decades [110]. The recurrence rate after modern radiation therapy is 
below 5%, and therefore equivalent to adjuvant carboplatin chemotherapy [99]. Patients 
treated with radiotherapy for testicular tumours are at an increased risk for secondary 
malignancies [111]. Treatment-related secondary tumours occur mostly in organs within the 
fields used for radiation treatment and the excessive risk appears ≥15 years after treatment 
[112]. On the other hand, the previously reported excessive risk of cardiovascular disease 
after radiation therapy [111] does not seem to materialise in patients treated with radiotherapy 
for stage I testicular seminoma [113], although this is controversial [114, 115].  
Modern adjuvant radiotherapy for stage I testicular seminoma is delivered with a lower dose 
[116] and on a smaller treatment volume [117-120] compared with historical practice 
patterns. The irradiation of the para-aortic region (superior border at T11/12, inferior border 
at L4/L5) with a dose of 20 Gy at 10 fractions of 2 Gy each is the current standard for 
adjuvant radiotherapy. Currently, the secondary malignancy risk after modern radiotherapy is 
probably a lot lower than that seen with the doses, volumes and techniques used in the past 
[121]. This risk may further decrease in the future with advances in radiotherapy [122]. 
In terms of costs, adjuvant radiotherapy and carboplatin chemotherapy are equal [123]. 
Nevertheless, carboplatin chemotherapy should be the preferred option for patients scheduled 
to undergo adjuvant treatment due to the possibility of increased late morbidity associated 
with radiotherapy [124] (especially increased risk for secondary malignancies). 
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Radiotherapy can be used in exceptional cases where carboplatin chemotherapy is not an 
option due to other medical conditions (for example impaired bone marrow function or 
severe cardiovascular morbidity) in patients at increased risk of recurrence. 
Recommendation 12.1: Adjuvant radiation therapy is not recommended for clinical stage I 
seminoma except in exceptional cases. 
Level of evidence: I 
Strength of recommendation: B 
Level of consensus: 100% (25) yes (25 voters)  
[Note to Ann Oncol: We bolded the term ‘not’ above to highlight that this is a 
recommendation against a particular practice - please can we retain this bolding in final 
publication] 
 
Stage II–III testicular cancer 
13. How should patients with stage IIA or IIB seminoma be treated?  
Radiotherapy has long been the standard treatment for patients with stage IIA and IIB 
seminoma [125-127]. Currently, the standard radiation field involves the para-aortic region 
and ipsilateral iliac nodes, with doses of 30 Gy in 2 Gy fractions for stage IIA, and 36 Gy in 
2 Gy fractions for stage IIB [125]. 
As an alternative to radiotherapy, cisplatin-based combination chemotherapy with three 
cycles of BEP or four cycles of etoposide/cisplatin (EP) have been evaluated in stage II 
seminoma, with good results [128, 129]. Carboplatin monotherapy has been evaluated but has 
shown significantly inferior results [130]. Combination therapy with carboplatin and 
radiotherapy has shown interesting results but remains investigational [126, 131]. 
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There are no randomised prospective data comparing treatment with radiotherapy to 
cisplatin-based combination chemotherapy in stage II seminoma, and both options are used 
interchangeably in clinical practice. A recent systematic review concluded that radiotherapy 
and cisplatin-based combination chemotherapy are equally effective in clinical stage IIA and 
IIB seminoma, with a trend in favour of chemotherapy in stage IIB because of fewer side 
effects and lower relapses rates [132]. In a recent retrospective data analysis from the United 
States national cancer database, with data from 2,437 patients with stage II seminoma, 
including 960 stage IIA and 812 stage IIB, radiotherapy was associated with improved 
survival compared with cisplatin-based combination chemotherapy for stage IIA patients, but 
no significant survival difference for stage IIB patients [133].  
Recommendation 13.1: Evidence of metastatic disease has to be unequivocal in order to 
make a diagnosis of clinical stage IIA seminoma. 
Level of evidence: V 
Strength of recommendation: A 
Level of consensus: 91% (29) yes, 3% (1) no, 6% (2) abstain (32 voters) 
Recommendation 13.2: Patients with clinical stage IIA seminoma can be treated with 
radiotherapy (30 Gy in 2 Gy fractions) or chemotherapy (three cycles of BEP or four cycles 
of EP). 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 43% (12) chemotherapy, 32% (9) radiotherapy, 18% (5) no preference, 
7% (2) abstain (28 voters) 
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Recommendation 13.3: Patients with clinical stage IIB seminoma should be treated with 
three cycles of BEP or four cycles of EP. Radiotherapy (36 Gy in 2 Gy fractions) should only 
be given in selected cases. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 91% (31) yes, 3% (1) no, 6% (2) abstain (34 voters) 
 
14. Should different chemotherapy regimens be used in different clinical scenarios of 
metastatic seminoma? 
Metastatic seminoma is less common than metastatic non-seminoma [104], and is associated 
with a comparatively good prognosis. Combination chemotherapy based on etoposide and 
cisplatin has been most commonly used either as a doublet (EP), or with the addition of 
bleomycin (BEP) or ifosfamide (VIP). Few trials have specifically investigated patients with 
seminoma; these patients were usually included alongside patients with NSGCT in trials of 
patients with a good prognosis. This makes specific recommendations for chemotherapy in 
seminoma difficult. The largest reported series, from Groupe d'Étude des Tumeurs 
Urogénitales (GETUG), Memorial Sloan Kettering Cancer Center (MSKCC), the UK MRC 
and the Swedish Norwegian Testicular Cancer Study Group, included prospective studies, 
and used four cycles of EP [134-137]. These studies showed very favourable outcomes in 
good prognosis metastatic seminoma, defining four cycles of EP as a standard of care in this 
setting. Additionally, in an EORTC/MRC study, which included 20% of good prognosis 
metastatic seminoma patients, three cycles of BEP showed a good level of efficacy (projected 
2-year progression-free survival [PFS] of 90.4%) [138] and is therefore also regarded as a 
standard of care.  
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As evidence supporting the value of bleomycin in metastatic seminoma is weak, four cycles 
of EP are a reasonable option in cases where bleomycin should be avoided (e.g. due to age, 
impaired renal function, significant lung disease or active smoking history).  
Four cycles of BEP or four cycles of VIP are options for patients with seminoma and 
intermediate prognosis [134].  
A single-centre UK study has shown that conventional-dose single-agent carboplatin 
(400 mg/m2) results in high rates of PFS in advanced seminoma [139]; however, a pooled 
analysis [140] that combined the UK data with those of a German study [141] reported 
significantly inferior 5-year PFS rates (72% versus 92%; P < 0.0001) and a trend towards 
poorer 5-year overall survival (OS) rates (89% versus 94%; P = 0.09) for single agent 
carboplatin versus cisplatin combination therapy [140]. Single-agent carboplatin use is 
therefore not routinely recommended and is only an option in cases where cisplatin is 
contraindicated (e.g. impaired renal function). Recent work has suggested better results can 
be obtained by the use of high-dose carboplatin (AUC 10) [142], but this should be regarded 
as investigational and requires confirmation in prospective studies.  
Recommendation 14.1: Three cycles of BEP is the recommended first-line chemotherapy for 
most good prognosis patients with metastatic seminoma. Four cycles of EP may be 
considered as an alternative. 
Level of evidence: II 
Strength of recommendation: A 
Level of consensus: 80% (24) yes, 10% (3) no, 10% (3) abstain (30 voters) 
Recommendation 14.2: Four cycles of EP should be considered as the alternative first-line 
chemotherapy for good prognosis patients with metastatic seminoma who are not suitable for 
bleomycin. 
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Level of evidence: II 
Strength of recommendation: A 
Level of consensus: 100% (30) yes (30 voters) 
Recommendation 14.3: Four cycles of BEP (or four cycles of VIP) should be considered in 
patients with intermediate prognosis seminoma. VIP is favoured in patients with 
contraindications to bleomycin. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: 94% (29) yes, 6% (2) abstain (31 voters) 
 
15. What is the optimal treatment for patients with clinical stage IIA and IIB non-
seminoma with normal or normalised serum tumour markers after orchiectomy?  
The optimal management of patients with clinical stage IIA and IIB non-seminoma is a 
matter of debate. Firstly, not all patients with a small-volume disease on CT scan ultimately 
demonstrate metastatic disease. For this reason, metastatic disease should be confirmed by 
US-guided biopsy or a confirmatory CT scan after approximately 8 weeks in patients 
presenting with retroperitoneal lymph nodes of <2 cm in the absence of other disease 
parameters (i.e. elevated serum tumour markers [STMs]). 
In patients with confirmed clinical stage II NSGCT, it is usual to initiate chemotherapy 
according to the prognostic risk category, with the possible exception of patients with stage 
IIA disease or those who have special rare histologies in the orchiectomy specimen (i.e. 
patients with teratoma and/or somatic-type malignant transformation) [61]. 
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The published literature indicates that the presence of elevated pre-RPLND STMs is 
associated with a 5.6-fold increased risk of systemic relapse and is the most significant 
predictor of relapse after primary RPLND [143, 144]. Hence, patients with elevated STMs 
should not be considered candidates for primary surgery. 
For patients with clinical stage IIA and IIB NSGCT and normal or normalised STMs, the 
overall cure rate is approximately 98%, regardless of the therapeutic option; therefore, 
maintaining efficacy while minimising toxicity is the chief driver of treatment decisions. 
Only two studies have compared primary RPLND (with or without adjuvant chemotherapy) 
with primary chemotherapy [145, 146]. The largest of these was a retrospective study of 
252 patients, in which primary chemotherapy was associated with improved 5-year relapse-
free survival (RFS) compared with RPLND (98% versus 79%; P < 0.001) [145]. In the other 
study, which had a prospective design and included 187 evaluable patients, relapse rates were 
similar between groups. Loss of ejaculation occurred in 32% of patients treated with primary 
RPLND and in 16% of those treated with primary chemotherapy. Acute chemotherapy 
toxicity was higher in the primary chemotherapy group [146]. 
In patients managed with primary RPLND, post-RPLND adjuvant chemotherapy with two 
cycles of EP has been associated with an RFS rate of 99% at a median follow-up of 8 years 
[147]. However, the indication for this treatment is not clearly defined, and it is mostly 
considered for patients with pN2 tumours. The alternative is surveillance, with chemotherapy 
in case of relapse [147, 148]. 
Patient counselling should focus on aspects such as: the need for post-chemotherapy RPLND 
in some patients treated with primary chemotherapy, relapse rates after RPLND only, the role 
of adjuvant chemotherapy after primary RPLND, and morbidity following each therapeutic 
choice. 
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Treatment options for stage IIA and IIB non-seminoma are shown in supplementary 
Table 2, available at Annals of Oncology online.  
Recommendation 15.1: All patients with clinical stage IIA NSGCT (evidence of enlarged 
retroperitoneal lymph nodes of <2 cm) and normal STMs should have metastatic disease 
confirmed (e.g. by biopsy or repeated imaging 8 weeks after surgery). 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: No vote obtained 
Recommendation 15.2: The recommended treatment for confirmed clinical stage IIA non-
seminoma with normal/normalised STMs is either BEP/EP ± NS-RPLND, or primary NS-
RPLND ± adjuvant chemotherapy. Discussion regarding the pros and cons of these options 
with the patient is recommended. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: 45% (13) BEP/EP ± NS-RPLND; 34% (10) NS-RPLND ± adjuvant 
chemotherapy; 7% (2) no preference, 14% (4) abstain (29 voters) 
Recommendation 15.3: The recommended treatment for clinical stage IIB non-seminoma 
with normal/normalised STMs is primary BEP/EP ± NS-RPLND. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 88% (29) BEP/EP ± NS-RPLND, 3% (1) NS-RPLND ± adjuvant 
chemotherapy, 6% (2) no preference, 3% (1) abstain (33 voters) 
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16. How should intermediate prognosis metastatic non-seminoma be treated? 
According to the International Germ Cell Consensus Classification Group (IGCCCG), 
intermediate prognosis metastatic non-seminoma is defined as a metastatic primary testicular 
(or retroperitoneal) NSGCT with at least one elevated tumour marker at an S2 level (hCG, α-
fetoprotein [AFP] or lactate dehydrogenase) and no extra-pulmonary visceral metastases (see 
supplementary Table 3, available at Annals of Oncology online) [149]. Until the mid-1990s, 
patients were usually included in trials of poor-prognosis NSGCT, and by default, standard 
treatment became four cycles of BEP plus surgery of the residual mass, since this approach 
became the standard of care in 1987 [150]. Replacement of bleomycin by ifosfamide does not 
improve outcome and increases haematotoxicity. However, four cycles of VIP can be 
delivered in specific situations when bleomycin needs to be avoided due to pulmonary 
contraindications and is associated with similar efficacy to four cycles of BEP [151, 152]. If 
VIP is being used, primary prophylactic granulocyte colony-stimulating factor (G-CSF) is 
recommended due the high risk of severe neutropaenia. 
Only one phase III trial has specifically focused on the IGCCCG-defined intermediate 
prognosis group of NSGCT. This trial compared four cycles of BEP with four cycles of 
paclitaxel plus BEP (T-BEP). In the intent-to-treat analysis, no significant difference was 
detected in PFS or OS, and more toxicity was reported with T-BEP than BEP [151]. 
Unfortunately, this trial was hampered by the fact that the planned accrual was not reached 
and by the erroneous randomisation of some patients with good or poor prognosis NSGCT. 
Recommendation 16.1: The recommended treatment for intermediate prognosis metastatic 
NSGCT is four cycles of BEP or four cycles of VIP with G-CSF support in cases where 
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bleomycin is contraindicated. Chemotherapy should be followed by resection of residual 
masses when present. 
Level of evidence: II 
Strength of recommendation: A 
Level of consensus: 89% (25) yes, 11% (3) abstain (28 voters) 
 
17. In patients with poor-prognosis NSGCT, should chemotherapy be intensified 
upfront, be adjusted based on tumour marker decline, or be administered using 
standard dosing schedules? 
Historically, the outcomes of IGCCCG-defined poor prognosis patients were disappointing, 
with 5-year PFS and OS rates of 41% and 48%, respectively [149]. A more recent 
retrospective analysis of 223 poor prognosis patients treated centrally with the standard 
treatment of four cycles of BEP reported 5-year PFS and OS rates of 55% and 64%, 
respectively [153]. Two randomised, controlled trials comparing four cycles of BEP to four 
cycles of VIP reported similar outcomes for both regimens in IGCCCG-defined poor 
prognosis patients [154]. Consequently, VIP is a recognised alternative to BEP if bleomycin 
needs to be replaced. 
Randomised trials directly comparing either dose-dense alternating regimens or primary high-
dose chemotherapy (HDCT) with subsequent autologous stem cell support to BEP alone in 
unselected poor prognosis patients have generally failed to demonstrate substantial 
improvements in treatment outcomes [155, 156]. The Intergroup US phase III trial that used 
two cycles of BEP followed by two cycles of HDCT, and compared this with four cycles of 
BEP, showed no improvement in PFS or OS in 174 patients with poor prognosis NSGCT 
[157]. A randomised, phase II UK MRC trial (TE23), which included 89 patients with poor 
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prognosis NSGCT, reported a 1-year PFS rate of 65% for patients undergoing intensified 
treatment with carboplatin/bleomycin/vincristine/cisplatin/BEP. Although the trial was not 
powered for comparison, results suggested that patients randomised to BEP achieved a 1-year 
PFS rate of only 43% [158]. A phase III EORTC trial evaluating primary sequential high-
dose VIP (HD-VIP) in 137 patients closed accrual early and reported a 2-year PFS rate of 
58% with HD-VIP versus 45% with four cycles of BEP (P = 0.057) [159]. In all trials, OS 
did not differ significantly between treatment groups, which may be related to the limited 
numbers of enrolled patients. 
The outcome of poor prognosis TGCC patients differs markedly depending on the presence 
of key prognostic features. The worst prognosis has been reported for patients with either a 
primary mediastinal NSGCT or non-pulmonary visceral metastases [160-163]. The only 
prospectively assessed predictor for treatment outcome and survival in poor prognosis 
NSGCT is the kinetics of decline in the STMs, hCG and AFP [157, 164-166]. Marker decline 
can be assessed by several methods, including marker half-life [165] and time-to-
normalisation (TTN) calculation, which also takes into account the extent of marker elevation 
above normal [166]. Notably, patients with very highly elevated markers (e.g. hCG 
500 000 mIU/mL) are more often identified as not achieving adequate marker decline when 
assessed by TTN. One major advantage of the TTN methodology relates to the fact that it 
provides early information for treatment decision-making, given that tumour marker decline 
is calculated just 3 weeks after the initiation of chemotherapy, before the second cycle is 
given [166]. The methodology was established using a retrospective cohort of 139 patients 
and showed that early tumour marker decline has a prognostic impact on both PFS (4-year 
PFS rates: 64% versus 38%, respectively, for patients with and without favourable tumour 
marker decline) and OS (83% versus 58%, respectively) [166]. Subsequently, it was 
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prospectively validated in the GETUG-13 phase III trial [164], where an impact on PFS 
(corresponding 3-year rates: 70% versus 48%) and OS (84% versus 65%) was confirmed. 
In the international GETUG-13 phase III trial, tumour marker decline was assessed after the 
first cycle of BEP. Patients with favourable decline (20%) were assigned to receive three 
more cycles of BEP, while patients with an unfavourable decline (80%) were randomised to 
undergo either three more cycles of BEP or a dose-dense alternating chemotherapy regimen 
adding paclitaxel, oxaliplatin and ifosfamide to the BEP drugs (bleomycin dose was also 
individualised according to pulmonary assessment). Early application of dose-dense 
chemotherapy significantly improved PFS (the primary endpoint of the study) in patients with 
an unfavourable decline (3-year PFS rate: 59% versus 48%; hazard ratio [HR] 0·66 [95% 
confidence interval (CI): 0.44–1.00], P = 0.05) [164]. The updated analysis (median follow-
up of 5.6 years) reported at ASCO 2016 confirmed the PFS benefit of early intensification (5-
year PFS: 60% versus 47%; HR 0.65 [95% CI: 0.43–0.97]; P = 0.037), and suggested a 
favourable, but non-significant long-term impact on survival (5-year OS: 70.4% versus 
60.8%; HR 0.69 [95% CI: 0.43–1.11], P = 0.12), with reversible toxicity (long-term side 
effects were similar after 5–6 years for patients who received BEP or dose-dense 
chemotherapy) [167].  
Recommendation 17.1: Tumour marker decline (i.e. using the GETUG risk calculator: 
https://www.gustaveroussy.fr/calculation-tumor/NSGCT.html) after one to two cycles of 
first-line cisplatin-based chemotherapy should be assessed to predict outcomes in poor 
prognosis patients.  
Level of evidence: II 
Strength of recommendation: B 
Level of consensus: 68% (17) yes, 8% (2) no, 24% (6) abstain (25 voters) 
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Recommendation 17.2: Tumour marker decline after one to two cycles of first-line cisplatin-
based chemotherapy should be used to guide treatment in poor prognosis patients with 
inadequate decline. 
Level of evidence: II 
Strength of recommendation: B 
Level of consensus: 71% (17) yes, 17% (4) no, 12% (3) abstain (24 voters) 
Recommendation 17.3: Early treatment intensification (dose-intensified chemotherapy) 
should be considered in the event of inadequate tumour decline after one to two cycles of 
first-line cisplatin-based chemotherapy. However, four cycles of BEP remains standard in 
patients with a favourable tumour decline.  
Level of evidence: II 
Strength of recommendation: C 
Level of consensus: 65% (17) dose intensification in selected patients, 23% (6) four cycles of 
BEP, 12% (3) dose intensification in all patients (26 voters) 
 
18. How should we treat primary mediastinal NSGCT (localised and metastatic)? 
Primary mediastinal NSGCT is a rare clinical and biological entity [168] characterised by a 
higher incidence in men with Klinefelter’s syndrome than in those without, and a higher 
frequency of the yolk sac tumour subtype, AFP secretion and TP53 alterations than in 
primary TGCCs [169]. Primary mediastinal NSGCT has a unique capacity to evolve to 
various haematological malignancies that contain the 12p isochromosome, which is both a 
distinct feature of TGCCs [170] and an indicator of poor outcome [171, 172]. These 
characteristics have led to the classification of primary mediastinal NSGCT as belonging to 
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the IGCCCG-defined poor prognosis subgroup, regardless of metastatic extent or tumour 
marker levels [149].  
Treatment for poor prognosis NSGCT is typically based on cisplatin-based chemotherapy and 
surgery (with an unclear sequence); however, due to the rarity of this disease, no level 1 
evidence is available from randomised trials. Post-chemotherapy, there is a high rate of 
residual and often chemorefractory cancer in patients with primary mediastinal non-
seminoma [173, 174]. Although not adequately assessed, the lower chemosensitivity of 
primary mediastinal NSGCT compared with other TGCCs means that primary surgery or 
early surgery after one to two cycles of chemotherapy in patients with localised disease may 
be advantageous to the classical sequence used in metastatic NSGCT (i.e. completion of 
chemotherapy followed by resection of residual masses). No data are available on the role of 
radiotherapy in primary mediastinal NSGCT. In contrast to other types of poor prognosis 
NSGCT, the benefit of early chemotherapy intensification for patients with an unfavourable 
decline in tumour markers is less clear for primary mediastinal NSGCT than for other tumour 
types [164]. Caution should be exercised with the use of bleomycin (conduct repeated lung 
function assessment and/or replace with ifosfamide) to limit the risk of pulmonary 
complications during thoracic surgery. 
All attempts should be made to achieve cure after first-line therapy because primary 
mediastinal NSGCT is generally non-curable in the salvage setting, even with HDCT and 
autologous transplant [168, 175, 176].  
Recommendation 18.1: For patients with primary mediastinal NSGCT, treatment with 
chemotherapy regimens used for poor prognosis NSGCT are recommended. Post-
chemotherapy surgery is recommended for all patients irrespective of marker status. 
Bleomycin should either be closely monitored to prevent clinical lung toxicity or replaced by 
ifosfamide. 
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Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 46% (12) chemotherapy, with intensification in case of unsatisfactory 
tumour marker decline, followed by surgery (if technically feasible), 23% (6) four cycles of 
BEP followed by surgery (if technically feasible), 19% (5) upfront intensified chemotherapy 
irrespective of tumour marker decline followed by surgery, 8% (2) four cycles of VIP 
followed by surgery (if technically feasible), 4% (1) primary surgery followed by 
chemotherapy (26 voters) 
 
19. What is the appropriate management for patients with upfront brain or bone 
metastases? 
Patients with upfront brain and/or bone metastases are rare and are classified as having a poor 
prognosis [149]. Optimal treatment remains unclear and is open for debate. There are no 
adequately powered prospective clinical trials to answer questions concerning reasonable 
imaging techniques, use of radiotherapy and/or the incorporation of additional surgery [163, 
177, 178]. All reports are based on retrospective data derived from small patient numbers or 
from single-centre experiences.  
Upfront brain metastases occur in approximately 1%–2% of patients with advanced TGCC 
[179]. Routine brain imaging is not recommended other than in patients with neurological 
symptoms, those with highly elevated hCG levels and multiple lung metastases or those with 
widespread disease [180]. A recently-published analysis including 228 patients with upfront 
brain metastases identified several adverse prognostic features such as histology, NSGCT 
mediastinal primary tumour and multiple (versus single) brain lesions [181]. Currently, 
patients with upfront brain metastases are treated with chemotherapy regimens recommended 
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for poor prognosis NSGCT according to the IGCCCG classification. The role of brain 
radiotherapy remains poorly defined, with several reports (including the recent pooled 
analysis) indicating no clear survival benefit and a risk of severe late neurotoxicity, including 
progressive leukoencephalopathy [181-183]. The role of brain surgery for post-chemotherapy 
residual masses is a relatively uncommon scenario as these patients often have widespread, 
multi-focal disease. However, patients with accessible, solitary or limited residual masses 
who showed a good response in other secondary sites and whose STMs have normalised, 
may be considered for post-chemotherapy resections. Long-term survival is reported in up to 
60% of such patients if complete resections can be achieved [178]. In contrast, a large 
retrospective analysis did not show any additional benefit of post-chemotherapy resections of 
residual brain lesions after first-line chemotherapy [181]. For patients with unresectable 
isolated residual brain metastases, stereotactic radiosurgery is considered as an option, though 
with a similarly low level of evidence. 
Upfront bone metastases are rare and are reported in about 3%–9% of patients, and are an 
adverse feature with poor treatment outcome, particularly in patients with non-seminoma. 
Bone metastases are mainly localised within the spine, pelvis and ribs. In a recent 
retrospective analysis of 123 patients with metastatic bone disease from TGCC, concomitant 
non-pulmonary visceral metastases and a mediastinal primary tumour were predictors of 
inferior outcome according to univariate analysis [184]. At present, no optimal treatment 
approach has been defined; however, patients with upfront bone metastases should be treated 
with chemotherapy regimens used for IGCCCG-defined poor prognosis NSGCT. The role of 
dose-intensified primary treatment and/or multimodal approaches, including additional local 
treatment by secondary resection and/or additional radiotherapy of residual bone lesions, 
could not be defined by the aforementioned retrospective analysis due to low patient numbers 
in the different subgroups [184]. Post-chemotherapy resections may be considered in 
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localised, accessible lesions, but decisions regarding post-chemotherapy surgery should be 
taken on an individual basis and by an experienced, multidisciplinary team. Post-
chemotherapy radiation might be an alternative to surgery [185-187]. 
Recommendation 19.1: Chemotherapy according to the IGCCCG classification for poor 
prognosis TGCC is recommended as standard of care for patients with upfront brain and/or 
bone metastases. Patients with upfront symptomatic or asymptomatic multiple brain 
metastases should commence systemic treatment before using other (local) treatment 
modalities. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: 100% (24) yes (24 voters) 
Recommendation 19.2: There are no high-quality data governing routine use of post-
chemotherapy local treatment (surgery or radiation) for the brain or bone. Primary whole-
brain radiotherapy is not recommended. 
Level of evidence: IV 
Strength of recommendation: C 
Level of consensus: 100% (24) yes (24 voters) 
[Note to Ann Oncol: We bolded the term ‘not’ above to highlight that this is a 
recommendation against a particular practice - please can we retain this bolding in final 
publication] 
Recommendation 19.3: Patients with upfront brain metastases, single residual lesions after 
chemotherapy and normal or normalised tumour markers should be considered for additional 
surgery or stereotactic radiation. 
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Level of evidence: V 
Strength of recommendation: A 
Level of consensus: 75% (18) additional surgery or stereotactic radiation, 25% (6) no further 
local treatment (24 voters) 
 
20. Poor prognosis NSGCT: when can orchiectomy be postponed and when should 
initial chemotherapy be reduced? 
Initial orchiectomy should not be performed in patients with TGCC and extended visceral 
metastases, in those with very elevated hCG or AFP (thus establishing the diagnosis of 
TGCC with no need for histological confirmation), and when patient conditions related to 
metastatic dissemination require immediate chemotherapy. In those cases, orchiectomy 
should be postponed until completion of chemotherapy, or at least until several weeks after 
chemotherapy has started when the general condition of the patient will allow it [188-191].  
There appears to be a partial blood-testicular barrier, which makes the testis a potential 
sanctuary for chemo-protected cancer cells. Studies have suggested that histological findings 
may vary if orchiectomy is postponed too long after completion of chemotherapy. In a series 
of 21 patients with delayed orchiectomy, necrosis, teratoma and viable cancer were found in 
13, 3 and 0 patients, respectively, among the 16 patients who had an orchiectomy 
immediately after completion of chemotherapy, whereas viable seminoma was found in three 
of the five patients where orchiectomy was delayed further (19–68 months; mean 
45.1 months) [190]. Moreover, discrepancies are found between the histology of the residual 
mass and that of the post-chemotherapy orchiectomy specimen: in a series of 352 patients, 
viable cancer and teratoma was found in 15% and 42% in the RPLND specimens compared 
with 21% and 30% of post-chemotherapy orchiectomy specimens, respectively [191]. In 
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another report of 42 patients, post-chemotherapy teratoma and viable cancer were reported in 
14 (33%) and 3 (7%) of the RPLND specimens, and in 15 (36%) and 12 (29%) of the 
orchiectomy specimens, respectively [188].  
Recommendation 20.1: In patients with advanced metastatic TGCC and/or those with 
impeding organ failure, orchiectomy can be postponed until the completion of chemotherapy. 
However, removal of the tumour-bearing testicle is mandatory after termination of 
chemotherapy or in-between cycles (without postponing the next cycle). 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 88% (28) yes, 12% (4) abstain (32 voters) 
In patients with widespread lung metastases, pure choriocarcinoma and high hCG, there is a 
high risk of fatal lung bleeding that often develops during the first days of chemotherapy. 
This complication can probably be reduced by avoiding full-dose chemotherapy during initial 
treatment. However, there are few data available on how to optimally administer such early 
induction chemotherapy.  
Recommendation 20.2: In patients with widespread lung metastases, pure choriocarcinoma 
and high hCG, 2–3 days of full dose cisplatin and etoposide are suggested, with continuation 
of chemotherapy when the patient has recovered (e.g. day 14). 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: No vote obtained  
In the majority of patients, pre-chemotherapy renal impairment is presumably due to 
mechanical obstruction from the malignant disease. In patients with a glomerular filtration 
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rate (GFR) of 30–50 mL/min/1.73 m2, after relief of mechanical obstruction 
(hydronephrosis), carboplatin-based chemotherapy (or cisplatin-based chemotherapy in 
patients undergoing haemodialysis) are options. Adapted doses of carboplatin are 
recommended in patients when it is believed that the impaired renal function is related to the 
cancer and may eventually recover. On the other hand, cisplatin can be used safely in patients 
with chronically impaired renal function who are undergoing haemodialysis. 
Recommendation 20.3: Patients with chronic kidney disease (stage II–III or GFR 50–
90 mL/min/1.73 m2) before treatment should have any hydronephrosis relieved to enable 
delivery of full-dose cisplatin-based chemotherapy with little risk of clinically relevant 
changes in GFR. 
Level of evidence: IV  
Strength of recommendation: B  
Level of consensus: 91% (30) yes, 9% (3) abstain (33 voters) 
Recommendation 20.4: In patients with a GFR of 30–50 mL/min/1.73 m2, carboplatin-based 
chemotherapy (or cisplatin-based chemotherapy in patients undergoing haemodialysis) are 
options. Bleomycin should be omitted.  
Level of evidence: V 
Strength of recommendation: C 
Level of consensus: No vote obtained 
Recommendation 20.5: Regardless of the degree of renal function, patients with 
hydronephrosis (unilateral or bilateral) should be relieved with either stent or nephrostomy 
prior to chemotherapy 
Level of evidence: V 
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Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 20.6: Patients with poor renal function should not be routinely treated with 
carboplatin but should be referred to high-volume centres for evaluation. 
Level of evidence: V 
Strength of recommendation: A 
Level of consensus: 100% (32) yes (32 voters) 
[Note to Ann Oncol: We bolded the term ‘not’ above to highlight that this is a 
recommendation against a particular practice - please can we retain this bolding in final 
publication] 
 
21. What is the optimal treatment of older patients with metastatic TGCCs?  
Data from 2,482 patients treated at two institutions in Germany suggest that there is a 
significant shift towards older age at diagnosis of TGCC (mean age at diagnosis increased 
from 28 to 36 years) [192], and this is paralleled by the increasing number of cases of 
seminomatous TGCC. Furthermore, poorer survival is observed for patients with metastatic 
TGCC aged >40 years [193-195], and this is partly attributable to the non-seminomatous 
histology in that age group. 
The optimal treatment of older patients with metastatic TGCC, as well as the optimal cut-off 
age to define older patients (e.g. 40, 50 or 60 years old), if any, is unknown. Many authors 
have reported data from retrospective analyses which suggest that increased age has a 
detrimental effect on OS [153, 196-198]. In a large Danish series [194], as well as in another 
double-institution dataset [198], age emerged as a statistically significant poor prognostic 
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factor in multivariate analyses. It is unknown whether this adverse outcome related to age is 
due to treatment deviating from standard recommendations, poor treatment tolerance or the 
underlying biology of the disease. In general, for patients aged >50 years, there are some 
concerns regarding the feasibility of administering standard chemotherapy and preserving the 
full dose and schedule of all drugs at each cycle. In the MSKCC experience, among 
236 patients aged ≥50 years, a high rate of neutropaenic fever and haematological severe 
toxicities were recorded, and dose reductions, delays or treatment changes were needed in 
30 patients [199]. However, in an English study, no substantial toxicities were reported with 
the use of chemotherapy in patients >60 years old [200]. 
Although the use of primary prophylaxis with G-CSF in young patients with TGCC receiving 
BEP is an area of debate [201, 202], G-CSF use may be indicated in selected high-risk cases 
among older patients. 
In the setting of second-line chemotherapy, where cure is still a realistic treatment goal, 
substantial uncertainties remain regarding the superiority of HDCT versus conventional-dose 
chemotherapy (CDCT) in both young adults and older patients with metastatic TGCC. Even 
in the context of salvage CDCT, the toxicity profiles of the most frequently utilised regimens 
(including ifosfamide and cisplatin combinations) in older patients is largely unknown. In the 
series of the European Society of Blood and Marrow Transplantation (EBMT) [203], 
1,169 patients aged >40 years received at least one cycle of HDCT from 1981 to 2015. In this 
study, age did not emerge as a significant prognostic factor for transplant-related mortality in 
multivariable analyses. Consequently, the administration of HD-carboplatin and etoposide 
appears feasible in older patients with advanced and relapsed TGCC. However, in the salvage 
setting, limited data are available regarding acute and long-term toxicities of dose-intensified 
regimens. 
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Recommendation 21.1: Comprehensive risk-benefit evaluation of older patients with TGCC 
should include assessment of co-morbidities and patient disease risk category.  
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: No vote obtained 
Recommendation 21.2: In the first-line setting, there is generally no reason not to administer 
standard chemotherapy according to the risk category. Primary G-CSF prophylaxis is 
recommended in these patients as the risk of neutropaenic sepsis is higher in older patients.  
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: No vote obtained 
Recommendation 21.3: Standard-dose chemotherapy may be the preferred choice in most 
elderly patients, although limited safety data are available. Referral to an experienced centre 
is strongly recommended to help make treatment decisions.  
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: No vote obtained 
 
22. Should care of patients with metastatic TGCC be centralised? 
In the last 20 years, many studies have emphasised a key role for centralisation of care for 
patients with rare cancers, especially those with TGCC, in order to achieve the best chance of 
cure and also to lower the likelihood of undue side effects related to over-treatment. Perhaps 
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the clearest demonstration for this was shown in an analysis of an EORTC/MRC phase III 
trial in patients with poor prognosis TGCC which looked at patient outcomes according to the 
experience of the treating centre, as assessed by the number of patients accrued in the trial 
(more or fewer than five patients). A reduction of approximately 20% in the chance of cure 
was observed in less experienced centres compared with more experienced centres [204]. 
Detailed analyses suggested that cumulative chemotherapy doses were lower, toxicity and 
treatment-related mortality were higher, and the use of post-chemotherapy resection of 
residual masses were lower in low volume centres, which may help to explain the poorer 
outcomes. These data, obtained from a large multi-national prospective trial, confirmed 
previous evidence from retrospective analyses of various databases from Europe and the US 
[205, 206]. In 1999, an editorial was subsequently written in the Journal of the National 
Cancer Institute where the authors called for treatment of patients with testicular cancer by 
experts at high volume centres [207].  
Since then, some countries, such as Denmark and England, have embraced a centralisation 
policy for all patients with TGCC. The Scandinavian SWENOTECA group has also been 
able to centralise chemotherapy delivery and surgery to several high-volume centres, with 
excellent outcomes at a national level [208]. In contrast, most other countries leave the 
decision and delivery of treatment to the local physician or medical team who first sees the 
patient. National surveys, when available, have repeatedly demonstrated that treatments 
administered differ from guidelines in several countries, possibly leading to higher relapse 
rates [209, 210]. Besides inadequate chemotherapy delivery (with a risk of over-treatment 
and excessive toxicity or insufficient treatment and poorer outcome), inadequate post-
chemotherapy RPLND or other resections of residual masses performed at community 
centres can also lead to a higher risk of in-field relapses compared with centralised care, as 
demonstrated in a German trial [102].  
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The benefits of centralised care include a pathological review of orchiectomy or other tissue 
material when needed, specialist radiological evaluation at diagnosis, post-chemotherapy, and 
during follow-up, guideline-based indication and delivery of chemotherapy and surgery by 
expert teams, all of which might be crucial for success. Models exist for the identification and 
development of high-volume specialist centres [211]. 
Recommendation 22.1: Besides orchiectomy, treatment of patients with TGCC should be 
conducted in high-volume centres. 
Level of evidence: IV 
Strength of recommendation: A 
Level of consensus: 77% (20) agree for all patients; 23% (6) agree only for patients with 
metastases (26 voters) 
 
Post-chemotherapy surgery, salvage chemotherapy, salvage and 
desperation surgery, and special topics 
23. When is post-chemotherapy retroperitoneal lymph-node dissection (PC-RPLND) 
indicated? 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Seminoma. 
Patients should be assessed for residual lesions by CT or MRI and tumour markers 
approximately 8 weeks after day 21 of last course of chemotherapy. Patients with a complete 
response should be scheduled for routine follow-up. For patients who do not achieve a 
complete response with remaining lesions >3 cm, an FDG-PET scan should be performed no 
earlier than 2 months after completion of chemotherapy. The negative predictive value of 
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FDG-PET is >90%, and a negative scan with a non-growing or regressing lesion warrants 
routine follow-up only [68]. With a positive FDG-PET scan, the possibility of residual 
seminoma is in the range of 20%, and so false-positive results are common [68, 212]. FDG-
PET-positive lesions can show an unpredictable behaviour; some lesions might decrease in 
size and activity over time. Thus, monitoring using repeat FDG-PET scans until resolution or 
progression is advised. PC-RPLND can be an alternative in resectable lesions, when a 
persistent FDG-PET positive residual mass is nodular in shape. However, the procedure is 
technically demanding, and often requires adjunctive procedures [68, 71, 213, 214]. In the 
majority of patients with seminoma, necrosis or fibrosis will be found at PC-RPLND. These 
patients require no further treatment [215].  
Non-seminoma. 
Patients should be assessed for residual masses by CT or MRI and tumour markers 
approximately 4–6 weeks after the start of the last chemotherapy cycle.  
PC-RPLND is indicated in patients with non-seminoma who have residual retroperitoneal 
lesions ≥1 cm in size, as determined by the largest axial dimension on CT scan in the 
presence of normal markers [215-222]. However, small residual lesions at or just above the 
1 cm cut-off may continue to decrease. Retrospective studies suggest that these patients can 
be treated individually using immediate post-chemotherapy surgery or short-term active 
monitoring in case of good prognosis disease. If these lesions do not continue to shrink on 
follow-up scans and remain ≥1 cm in largest axial diameter, they should be resected. Patients 
with residual lesions <1 cm (including those with complete clinical remission) have a <10% 
relapse risk, presumably due to residual teratoma or viable cancer. Treatment for these 
patients includes either active monitoring or PC-RPLND, which should be discussed 
individually [223-226]. 
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Patients with post-chemotherapy residual lesions and positive STMs should be followed with 
STM determinations at brief intervals and should not undergo surgery immediately. Patients 
with declining STMs or low-level STM stabilisation are candidates for surgery, whereas 
patients with increasing STMs, especially a rising β-hCG, should undergo full salvage 
chemotherapy before residual tumour resection is considered. 
Treatment decisions in patients with post-chemotherapy positive STMs and potentially 
resectable lesions are complex and must take into account the location of the primary tumour 
(primary mediastinal non-seminoma versus others), the type of elevated STM (e.g. β-hCG is 
of more concern than AFP), the degree of post-chemotherapy STM elevation, STM kinetics, 
and the location, number and resectability of the lesions.  
Recommendation 23.1: PC-RPLND is indicated in patients with non-seminoma and residual 
retroperitoneal lesions ≥1 cm in size. 
Level of evidence: IV 
Strength of recommendation: A 
Level of consensus: 89.3% (25) yes, 10.7% (3) no, 0% (0) abstain (28 voters) 
Recommendation 23.2: Indication for PC-RPLND should be determined based on the largest 
axial dimension of residual retroperitoneal lesions on CT scan in the presence of normal 
markers. 
Level of evidence: IV 
Strength of recommendation: A 
Level of consensus: 100% (28) yes (28 voters) 
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24. Salvage Therapy 
Salvage surgery. 
Salvage surgery refers to surgery in patients with relapsing or progressing disease following 
salvage chemotherapy, as an alternative to palliative chemotherapy. A proportion of these 
patients may benefit from complete removal of disease, with long-term survival reported in 
selected patients [227-229]. Ideal candidates include patients with resectable radiological 
lesions in the retroperitoneum and potentially one additional site, those with declining STMs 
or a STM plateau after chemotherapy, and patients with a slowly rising AFP. Viable cancer 
or teratoma with somatic-type malignant transformation is more frequent after salvage or 
desperation surgery [109].  
Salvage chemotherapy. 
Patients who relapse or progress after three or more cycles of cisplatin-based first-line 
chemotherapy for metastatic disease can be cured by salvage chemotherapy. Treatment 
decisions about salvage chemotherapy are complex, taking into account multiple factors, 
including primary tumour location, histology, response to first-line chemotherapy, location of 
metastases and tumour marker levels at the time of relapse or progression. These patients 
should therefore be referred to high-volume centres with individual decisions made by a 
multidisciplinary team experienced in treating such patients [230]. 
First-salvage chemotherapy. 
The prognosis of patients who progress or relapse after first-line chemotherapy for metastatic 
disease, comprising at least three cisplatin-based cycles, should be assessed and classified 
using the international prognostic factor classification (supplementary Table 4, available at 
Annals of Oncology online) [231]. There is insufficient evidence to determine whether CDCT 
or HDCT produces superior outcomes as first-salvage chemotherapy. Therefore, either CDCT 
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or HDCT are acceptable options for first-salvage chemotherapy. Salvage CDCT should be 
delivered as four cycles of cisplatin/ifosfamide-based triple-drug combinations. The two most 
widely used CDCT regimens are cisplatin/ifosfamide/paclitaxel (TIP) using different 
schedules [232, 233] and VIP (Table 2) [234, 235]. Salvage HDCT is delivered as two or 
three sequential cycles of high-dose carboplatin and etoposide without additional agents such 
as ifosfamide, cyclophosphamide or thiotepa [236-238]. Paclitaxel and ifosfamide are used 
prior to HDCT (carboplatin/etoposide) for two cycles in the TI-CE regimen [236]. One study 
used a single cycle of VIP prior to HDCT [237]. As neither CDCT nor HDCT has 
unequivocal superiority as first-salvage treatment, patients should, where possible, be treated 
in the prospective randomised phase III TIGER trial (NCT02375204) comparing CDCT, TIP, 
HDCT and TI-CE [239]. 
Second-salvage chemotherapy. 
HDCT should be considered as second-salvage treatment in patients with a good performance 
status and adequate organ function who relapse or progress with systemic disease and/or 
increasing tumour markers after first-salvage CDCT [196, 240]. 
Selected ‘third-line’ regimens are suitable for patients relapsing after HDCT, or in cases 
where HDCT cannot be performed. In individual patients, cures may still be achievable using 
these regimens (see Table 3) followed by surgical resection of residual masses or using 
desperation surgery alone. 
Recommendation 24.1: In patients with disease relapse, immediate surgery without prior 
biopsy should only be considered for: 
• non-seminoma patients relapsing with localised resectable lesions and negative STMs, as 
lesions may be due to enlarging teratoma without malignant components 
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• late relapses in both seminoma and non-seminoma due to the high incidence of 
chemotherapy-refractory disease. 
Level of evidence: V 
Strength of recommendation: A 
Level of consensus: 76.5% (26) yes, 5.9% (2) no, 17.6% (6) abstain (34 voters) 
Recommendation 24.2: In all other patients, particularly those with increasing STMs, surgery 
should be postponed until completion of salvage chemotherapy, even in the presence of 
resectable lesions. 
Level of evidence: III 
Strength of recommendation: A 
Level of consensus: 87.5% (28) yes, 12.5% (4) abstain (32 voters)  
 
25. Salvage treatment for patients with brain metastases 
Patients who relapse or progress with brain metastases after first-line cisplatin-based 
chemotherapy have a poor prognosis, but cure can be achieved in individual cases by 
multimodality treatment, preferably including HDCT plus radiation and/or surgery [178, 
181]. With current optimised treatments in men with poor-risk NSGCT, for those who 
experience a relapse, it was not uncommon that brain was the only relapse site, and this raises 
the question of systematic early detection and optimal treatment of brain metastases [241]. 
In the rare case of an isolated brain relapse without evidence of systemic disease, prognosis 
appears to be better only in patients with a single brain metastasis. Surgery as well as 
stereotactic radiation, with or without chemotherapy, are valid options. When radiotherapy is 
63 
 
considered, stereotactic radiation should be used rather than whole brain radiation whenever 
technically feasible. 
Recommendation 25.1: Surgery as well as stereotactic radiation with or without 
chemotherapy may be considered for patients with isolated brain relapse without evidence of 
systemic disease. When radiotherapy is considered, stereotactic radiation should be used 
rather than whole brain radiation whenever technically feasible. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 53.3% (16) yes, 26.7% (8) no, 20.0% (6) abstain (32 voters) 
 
Survivorship and follow-up schemes 
Most of the recommendations given in this chapter are based on cross-sectional studies, 
typically covering the first decade after treatment. Further, age-matched control groups are 
often missing such that the effect of ageing is not easy to disentangle. As such, uncertainty 
remains regarding the longer-term survivorship outcomes and causal relationships. This 
uncertainty is reflected by low levels of evidence (IV–V) and lower grades of 
recommendation (usually B). 
26. How can post-therapeutic psychosocial issues be minimised, and health-related 
quality of life (HRQoL) protected? 
HRQoL: emotional and psychosocial issues. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Quality of life and post-therapeutic psychosocial issues. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
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Recommendation 26.1: Patients should be informed of the potential long-term toxicities of 
treatment (i.e. ototoxicity and neurotoxicity, second cancers and cardiovascular disease 
[CVD], as well as sexual difficulties, fatigue and cognitive dysfunction). 
Level of evidence: III/IV 
Strength of recommendation: B 
Level of consensus: 97% (32) yes, 3% (1) abstain (33 voters) 
Recommendation 26.2: Patients should be reassured that in most cases, long-term overall 
HRQoL is similar to that in men who have not undergone treatment for testicular cancer. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 97% (32) yes, 3% (1) abstain (33 voters) 
Recommendation 26.3: Vulnerable patients (e.g. those with psychological distress and poor 
social support) should be identified early to assess the need for support by social workers and 
psychological assistance. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 97% (32) yes, 3% (1) abstain (33 voters) 
Recommendation 26.4: Physical activity and a healthy lifestyle should be recommended to 
all patients. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 97% (32) yes, 3% (1) abstain (33 voters) 
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27. How should fatigue be identified, prevented and treated?  
Chronic fatigue 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Recommendation 27.1: In order to prevent fatigue, overtreatment should be avoided (i.e. by 
adherence to treatment guidelines).  
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 27.2: Fatigue should be addressed and documented during follow-up. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 27.3: Contributing conditions should be identified and treated. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 27.4: Personalised physical training should be recommended. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 27.5: Referral for cognitive behavioural therapy should be considered. 
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Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
 
28. How can the risk of ototoxicity and neurotoxicity be minimised? 
Ototoxicity. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Neurotoxicity. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Recommendation 28.1: Symptomatic ototoxicity and neurotoxicity are unpreventable 
complications of cisplatin-based chemotherapy and should generally not influence treatment 
intensity. 
Level of evidence: III 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
[Note to Ann Oncol: We bolded the term ‘not’ above to highlight that this is a 
recommendation against a particular practice - please can we retain this bolding in final 
publication] 
Recommendation 28.2: Patients should be informed about the risk of ototoxicity and 
neurotoxicity before receiving cisplatin-based chemotherapy.  
Level of evidence: IV 
Strength of recommendation: B 
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Level of consensus: 100% (33) yes (33 voters) 
Recommendation 28.3: Further risk factors for ototoxicity and neurotoxicity should be 
avoided (e.g. aminoglycosides within weeks of chemotherapy, exposure to loud noises, 
smoking and poorly regulated diabetes). 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
 
29. Which testicular germ cell cancer survivors (TGCCSs) should be offered 
testosterone replacement therapy? 
Leydig cell dysfunction and testosterone. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Recommendation 29.1: Asymptomatic TGCCSs with testosterone levels below the normal 
range should not routinely be offered testosterone replacement therapy. 
Level of evidence: V 
Strength of recommendation: C 
Level of consensus: 74% (20) yes, 19% (5) no, 7% (2) abstain (27 voters) 
Recommendation 29.2: TGCCSs with testosterone levels below the normal range and 
clinical symptoms* should be offered testosterone replacement therapy. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
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Recommendation 29.3: TGCCSs with low testosterone levels and clinical symptoms* which 
resolve after short-term (3–6 months) testosterone substitution should continue testosterone 
replacement therapy. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 94% (30) yes, 6% (2) abstain (32 voters) 
Recommendation 29.4: TGCCSs with normal testosterone levels and clinical symptoms* 
which resolve after short-term (3–6 months) testosterone substitution should not continue 
testosterone replacement therapy. 
Level of evidence: V 
Strength of recommendation: C 
Level of consensus: 44% (11) yes, 12% (3) no, 44% (11) abstain (25 voters) 
*Clinical symptoms: decreased sexual function (often including loss of morning- and 
spontaneous erection), less active and more sedate lifestyle. 
[Note to Ann Oncol: We bolded the term ‘not’ above to highlight that this is a 
recommendation against a particular practice - please can we retain this bolding in final 
publication] 
 
Semen cryopreservation. 
Semen quality is reduced prior to orchiectomy due to testicular cancer, and sperm count and 
concentration decrease further after orchiectomy [242, 243]. Thus, all patients should be 
offered semen preservation before initiation of treatment, preferably prior to orchiectomy. 
Patients who subsequently receive chemotherapy or radiotherapy in particular should be 
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encouraged to undertake semen preservation, as their fertility is further decreased compared 
with those who undergo orchiectomy alone [244-249]. If cryopreservation is not possible 
before the start of treatment, fatherhood may still be possible in the majority of patients via 
natural conception or in vitro fertilisation. Obviously, patients whose treatment involves 
bilateral orchiectomy or contralateral testicular radiotherapy due to GCNIS should, in 
particular, be informed about a pre-treatment sperm preservation programme. 
 
30. How can the risk of CVD be reduced in TGCCSs? 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Recommendation 30.1: In order to reduce the risk of CVD, overtreatment should be avoided, 
especially the combination of chemotherapy and radiotherapy. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 30.2: Patients should receive repeated counselling about the importance of 
a healthy lifestyle in preventing CVD. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 30.3: Patients should receive regular check-ups to prevent CVD, including 
measurements of blood pressure, weight, sex hormones, lipids and glucose. 
Level of evidence: IV 
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Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
Recommendation 30.4: Patients should receive treatment for hypertension, 
hypercholesterolaemia and diabetes to prevent CVD. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 100% (33) yes (33 voters) 
 
31. How can the risk of a second cancer and its consequences be reduced in TGCCSs? 
Second non-germ cell cancer. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Second germ cell testicular cancer. 
See Section 3 of the supplementary text, available at Annals of Oncology online. 
Recommendation 31.1: TGCCSs who receive treatment in addition to orchiectomy should be 
informed about the risk of second cancers and the importance of contacting their healthcare 
provider if suspicious symptoms arise. 
Level of evidence: V 
Strength of recommendation: B 
Level of consensus: 94% (31) yes, 6% (2) no (33 voters) 
Recommendation 31.2: TGCCSs should receive lifestyle counselling and be encouraged not 
to smoke. 
Level of evidence: V 
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Strength of recommendation: B 
Level of consensus: 94% (31) yes, 6% (2) no (33 voters) 
 
32. How should follow-up schedules be planned? 
Follow-up of TGCCSs on active surveillance or in remission after treatment for the first 
five years. 
The primary aim of follow-up in the first 5 years is the timely diagnosis of recurrent disease 
in order to treat the patient with curative intent using the least aggressive therapy [50]. An 
adequate follow-up relies on profound knowledge about testicular cancer with regards to 
histology, stage, primary treatment and treatment success. Follow-up may require tailoring of 
individual schedules to ensure they are acceptable for the patient, physician and the 
healthcare system. The interval of follow-up visits and the tests to be performed at each visit 
should depend on the risk of relapse in general and on the likely site of relapse in particular 
[250]. Only one randomised trial is available regarding the implications of different follow-
up schedules and the respective use of imaging and tumour markers [251]. All published 
guidelines regarding follow-up therefore rely on information from case series reports or 
therapeutic trials. However, several recent publications have added valuable information, 
enhancing the basis for the formulation of evidence-based recommendations [78, 80, 89, 92, 
98, 99, 197, 252, 253]. 
For a long time, most recommendations included tight schedules with extensive imaging 
using CT scans. However, with the recognition of the risk of carcinogenesis due to ionising 
radiation from CT scanning [254], most guidelines have reduced the recommended number 
of CT scans [61, 255].  
72 
 
When considering the risks of relapse depending on diagnosis and initial treatment, three 
major follow-up groups can be defined:  
1)  Patients with seminoma stage I 
2)  Patients with non-seminoma stage I on active surveillance 
3)  All patients who, having received either adjuvant treatment or curative 
chemotherapy for good and intermediate prognosis metastatic disease (according to 
the IGCCCG classification), have achieved complete remission with or without 
surgery (for seminoma this includes residual lesions <3 cm or residual lesions ≥3 cm 
that are PET-negative) 
It is important to note that patients not achieving complete remission or presenting with poor 
prognosis disease should receive individualised follow-up, ideally in specialised centres.  
Recommendation 32.1: When considering the risks of relapse depending on diagnosis and 
initial treatment, all seminoma stage I patients should be grouped together. 
Level of evidence: IV 
Strength of recommendation: B 
Level of consensus: 88% (29) yes, 6% (2) no, 6% (2) abstain (33 voters) 
Tables 4–6 show the recommended schedules for minimal follow-up of the above three 
groups based on the discussions and voting by the group of experts at the consensus 
conference.  
Generally, MRI of the abdomen can be used instead of CT in experienced centres. Regarding 
the use of ultrasound of the contralateral testis, the majority of the consensus panel members 
recommend no regular ultrasound both in the case of a negative biopsy (68% [21 of 31 panel 
73 
 
members]) and also if no contralateral biopsy had been performed (53% [17 of 32 panel 
members]). 
Follow-up of TGCCSs beyond 5 years. 
Follow-up for relapse beyond five years is generally not recommended. According to a 
population-based analysis, very late relapse (VLR) after 5 years is a rare event occurring in 
approximately 0.5% of patients [256]. Thus, the aim of follow-up beyond 5 years shifts to the 
detection of the late side effects of treatment. As patients with TGCC who receive >1 line of 
treatment for disseminated disease have a highly increased risk of late toxicity and death as a 
result of causes other than TGCC, life-long follow-up has been suggested for those cases 
[257]. Survivorship care plans (see below) are recommended for all patients. Most patients 
with VLR are diagnosed due to symptoms; however, elevated tumour markers can be 
detected in both seminomatous and NSGCTs in up to 50% of patients [256, 258]. Patient 
education and physician awareness of relapse symptoms are therefore very important in 
survivorship management. The early use of imaging and tumour markers is encouraged if 
relapse is suspected. 
 
33. Survivorship care plan 
An example of a patient care plan to be provided to the patient and their general practitioner 
at termination of uro-oncological follow-up is provided in supplementary Table 5, available 
at Annals of Oncology online.  
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TABLES 
Table 1. Levels of evidence and grades of recommendation (adapted from the Infectious 
Diseases Society of America-United States Public Health Service Grading System [259]) 
Levels of evidence 
I Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for bias) or meta-analyses of well-
conducted randomised trials without heterogeneity 
II Small randomised trials or large randomised trials with a suspicion of bias 
(lower methodological quality) or meta-analyses of such trials or of trials 
with demonstrated heterogeneity 
III Prospective cohort studies 
IV Retrospective cohort studies or case-control studies  
V Studies without control group, case reports, experts’ opinions 
Grades of recommendation 
A Strong evidence for efficacy with a substantial clinical benefit, strongly 
recommended 
B Strong or moderate evidence for efficacy but with a limited clinical benefit, 
generally recommended 
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the 
disadvantages (adverse events, costs, ...), optional  
D Moderate evidence against efficacy or for adverse outcome, generally not 
recommended 
E Strong evidence against efficacy or for adverse outcome, never recommended 
By permission of the Infectious Diseases Society of America [259]. 
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Table 2. First-salvage regimens for CDCT and HDCT [104, 234, 235] 
CDCT regimens 
VIP/PEI  Four cycles, repeat every 3 weeks 
    Cisplatin 20 mg/m2 Day 1–5 
    Etoposide 100 mg/m2 Day 1–5 
    Ifosfamide 1.2 g/m2 Day 1–5 
TIP  Four cycles, repeat cycle every 3 weeks 
    Paclitaxel 250 mg/m2 Day 1 
    Cisplatin 25 mg/m2 Day 2–5 
    Ifosfamide 1.5 g/m2 Day 2–5 
HDCT regimens 
TI-CE  Two TI cycles to be repeated after 2 weeks 
     Paclitaxel  200 mg/m2 Day 1 
     Ifosfamide  2 g/m2  Days 2–4 
  Followed by:  Three CE cycles to be repeated after 3 weeks 
     Carboplatin AUC 8 Days 1–3 
     Etoposide  400 mg/m2 Days 1–3 
VIP-CE   One VIP cycle 
     Cisplatin  20 mg/m2 Days 1–5 
     Etoposide  100 mg/m2 Days 1–5 
     Ifosfamide  1.2 g/m2 Days 1–5 
  Followed by:  Three CE cycles to be repeated after 3 weeks 
     Carboplatin 500 mg/m2 Days 1–3 
     Etoposide  500 mg/m2 Days 1–3 
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Indiana-CE   Two cycles to be repeated after haematopoietic recovery 
    Carboplatin 700 mg/m2 Days 1–3 
    Etoposide  750 mg/m2 Days 1–3 
AUC, area under the curve; CDCT, conventional-dose chemotherapy; CE, 
carboplatin/etoposide; HDCT, high-dose chemotherapy; TI, paclitaxel/ifosfamide; TIP, 
paclitaxel/ifosfamide/cisplatin; VIP/PEI, etoposide/ifosfamide/cisplatin. 
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Table 3. ‘Third-line’ regimens used for second or subsequent salvage treatment 
 
Single agent 
Regimen Dose Schedule Reference 
Gemcitabine 1000 mg/m2 d1, 8,15 q3w [260]  
 1200 mg/m2 d1, 8,15 q3w 
 
[261] 
Oxaliplatin 60 mg/m2 or  
85 mg/m2  
 
d1, 15 q4w [262]  
Paclitaxel 170 mg/m2 d1, q3w [263] 
 225 mg/m2 d1, q3w [264]  
 250 mg/m2 d1, q3w [265]  
 250 mg/m2 d1, q3w [266] 
Oral Etoposide 50 mg/m2/day Continuously [267]  
Two drug combinations 
Regimen Dose Schedule Reference 
Gemcitabine 
 
Oxaliplatin 
1000 mg/m2or 
1250 mg/m2 
130 mg/m2 
d1, 8 q3w 
 
d1, q3w 
[268-270] 
 
  
Gemcitabine 
Paclitaxel 
1000 mg/m2 
100 mg/m2  
d1, 8, 15 q4w 
 
[271, 272] 
 
Three drug combinations 
Regimen Dose Schedule Reference 
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Gemcitabine 
Oxaliplatin 
Paclitaxel 
800 mg/m2 
130 mg/m2 
80 mg/m2 
d1, 8 q3w 
d1, q3w 
d1, 8 q3w 
[273]  
Gemcitabine 
Cisplatin 
Paclitaxel 
800 mg/m2 
50 mg/m2 
80 mg/m2 
d1, 8 q3w 
d1, 8 q3w 
d1, 8 q3w 
 
 
[274]  
d, day; q3w, every 3 weeks; q4w, every 4 weeks. 
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Table 4. Recommended minimal follow-up for seminoma stage I on active surveillance 
or after adjuvant treatment (carboplatin or radiotherapy) 
Modality Year 1 Year 2 Year 3 Years 4+5 
After 
5 years 
Tumour 
markers +/- 
doctor visit* 
2 times 2 times 2 times 1 time Further 
management 
according to 
survivorship 
care plan 
Chest X-
ray** 
0 0 0 - 
Abdominal 
CT/MRI*** 
2 times 2 times 1 at 
36 months 
1 at 
60 months 
* Level of evidence: V; strength of recommendation: B; level of consensus: 97% (33) yes, 
3% (1) abstain (34 voters) (In general, patients are seen by a doctor during follow-up, but 
some routine control visits may be performed by specially trained nurses) 
** Level of evidence: V; strength of recommendation: B; level of consensus: 88% (28) yes, 
3% (1) no, 9% (3) abstain (32 voters) 
*** Level of evidence: V; strength of recommendation: B. Schedule based on previous 
follow-up recommendations provided by international groups, including ESMO. Pelvic 
imaging should also be included for patients with an increased risk of pelvic recurrence (i.e. 
bulky abdominal disease [>5 cm], prior history of maldescent testis or orchidopexy, history 
of previous scrotal surgery, invasion of the carcinoma into the tunica vaginalis of the testis) 
(Level of evidence: III; strength of recommendation: B) [275]. 
CT, computed tomography; ESMO, European Society for Medical Oncology; MRI, magnetic 
resonance imaging. 
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Table 5. Recommended minimal follow-up for non-seminoma stage I on active 
surveillance 
Modality Year 1 Year 2 Year 3 Year 4+5 
After 
5 years 
Tumour 
markers +/- 
doctor visit* 
4 timesa 4 times 2 times 1-2 times Further 
management 
according to 
survivorship 
care plan 
Chest X-ray** 2 2 1 if LVI+ At 
60 months if 
LVI+ 
Abdominal 
CT/MRI*** 
2 times At 
24 monthsb 
At 
36 monthsc 
(optional) 
At 
60 monthsc 
(optional) 
* Level of evidence: V; strength of recommendation: B; level of consensus: 97% (33) yes, 
3% (1) abstain (34 voters) (In general patients are seen by a doctor during follow-up, but 
some routine control visits may be performed by specially trained nurses) 
** Level of evidence: V; strength of recommendation: B; level of consensus to abandon chest 
X-ray: 3% (1) yes, 88% (30) no, 9% (3) abstain (34 voters) 
*** Level of evidence: V; strength of recommendation: B. Schedule based on previous 
follow-up recommendations provided by international groups, including ESMO. Pelvic 
imaging should also be included for patients with an increased risk of pelvic recurrence (i.e. 
bulky abdominal disease [>5 cm], prior history of maldescent testis or orchidopexy, history 
of previous scrotal surgery, invasion of the carcinoma into the tunica vaginalis of the testis) 
(Level of evidence: III; strength of recommendation: B) [275]. 
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aIn high-risk patients (LVI+), a minority of consensus panel members recommended 
six assessments in Year 1 instead of four. Level of consensus: 39% (12) yes, 55% (17) no, 
6% (2) abstain (31 voters) 
bIn high-risk patients (LVI+), the majority of consensus panel members recommended an 
additional CT scan at 18 months. Level of consensus: 62% (21) yes, 32% (11) no, 6% (2) 
abstain (34 voters) 
cAlmost half of consensus panel members recommended additional scans at 36 and 
60 months. Level of consensus: 47% (16) yes, 44% (15) no, 9% (3) abstain (34 voters). 
CT, computed tomography; ESMO, European Society for Medical Oncology; LVI, 
lymphovascular invasion; MRI, magnetic resonance imaging. 
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Table 6. Recommended minimal follow-up after adjuvant treatment or complete 
remission for advanced disease (excludes patients with a poor prognosis or no 
remission) 
Modality Year 1 Year 2 Year 3 Year 4+5 
After 
5 years 
Tumour 
markers +/- 
doctor visit* 
4 times 4 times 2 times 2 times Further 
management 
according to 
survivorship 
care plana 
Chest X-ray** 1-2 1 1 1 
Abdominal 
CT/MRI*** 
1-2 times At 24 
months 
1 at 36 
months 
(optional) 
1 at 60 
months 
(optional) 
Thorax 
CT**** 
- - - - 
* Level of evidence: V; strength of recommendation: B; level of consensus: 97% (33) yes, 
3% (1) abstain (34 voters) (In general patients are seen by a doctor during follow-up, but 
some routine control visits may be performed by specially trained nurses) 
** Level of evidence: V; strength of recommendation: B; level of consensus to abandon chest 
X-ray: 3% (1) yes, 94% (32) no, 3% (1) abstain (34 voters) 
*** Level of evidence: V; strength of recommendation: B. Schedule based on previous 
follow-up recommendations provided by international groups, including ESMO. Pelvic 
imaging should also be included for patients with an increased risk of pelvic recurrence (i.e. 
bulky abdominal disease [>5 cm], prior history of maldescent testis or orchidopexy, history 
of previous scrotal surgery, invasion of the carcinoma into the tunica vaginalis of the testis) 
(Level of evidence: III; strength of recommendation: B) [275] 
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**** Same time points as abdomino-pelvic CT/MRI in case of pulmonary metastases at 
diagnosis. Level of evidence: V; strength of recommendation: B. Schedule based on previous 
follow-up recommendations provided by international groups, including ESMO. 
aIn case of teratoma in resected residual disease, patient follow-up should remain with uro-
oncologist. 
CT, computed tomography; ESMO, European Society for Medical Oncology; MRI, magnetic 
resonance imaging. 
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[Note to Annals: Refs Ilic, Misso. Cochrane Rev 2011 and Albers et al Cochrane Rev 2014 do 
not have a volume number and are therefore correct as written below] 
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SUPPLEMENTARY TEXT 
 
SECTION 1: INTRODUCTION 
Testicular germ cell cancer (TGCC) accounts for only 1%–2% of tumours in men overall, but 
is the most commonly diagnosed malignancy in young men [1]. The incidence of TGCC 
varies by ethnic origin, with the highest rates reported in developed countries and the lowest 
in developing countries [2]. The European Society for Medical Oncology (ESMO) Clinical 
Practice Guideline (CPG) provides high-level guidance on optimal strategies for the 
diagnosis, treatment and follow-up of patients with TGCC [3, 4]. However, some issues 
relating to the optimal management of patients with TGCC remain controversial and warrant 
further discussion and clarification. Accurate diagnosis of stage and type of testicular cancer 
is also a concern since testicular cancers are one of the most diverse areas of human 
pathology and pathologists may see few tumours in a year [5-8]. 
Regarding the treatment of TGCC, the optimal use of adjuvant chemotherapy in stage I 
disease remains an area of controversy. Defined strategies to accurately identify those 
patients who require adjuvant chemotherapy could therefore protect low-risk patients from 
the toxicities associated with over-treatment. The optimal treatment approach for stage IIA 
and IIB seminoma and non-seminoma is also a matter of debate and is discussed in this 
manuscript. Other areas which are currently only supported by marginally higher levels of 
evidence, but nonetheless often require treatment decisions in clinical practice, are issues of 
post-chemotherapy surgery, salvage chemotherapy and salvage and/or desperation surgery. 
Finally, given the excellent prognosis of most patients with TGCC, high quality follow-up 
care and survivorship care plan recommendations are crucial. Indeed, the long-term global 
health-related quality of life (HRQoL) of testicular germ cell cancer survivors (TGCCSs) is 
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similar to that of the general population [9], although chronic side effects can adversely affect 
HRQoL, particularly after chemotherapy [10, 11]. However, the optimal follow-up of 
TGCCSs has not yet been defined and is an unmet need. 
Collectively, these and other topics represent points in the care pathway where a consistent 
approach between physicians is lacking. Given these unresolved and complex issues, the aim 
of this consensus conference was to produce multidisciplinary evidence-based guidelines on 
selected clinically relevant questions that complement the existing ESMO CPG where 
possible and facilitate an optimal and consistent approach to the diagnosis, treatment and 
follow-up of patients with testicular cancer. 
 
SECTION 2: METHODS 
Leading up to the consensus conference, all five working group chairs developed clinically 
relevant questions surrounding their given subject area, which were subsequently discussed 
with their group members and modified as needed. Key literature relevant to the subject areas 
and questions were then reviewed by each working group prior to the consensus conference 
in order to draft preliminary recommendations. No systematic literature search was 
undertaken. During the conference, preliminary recommendations were discussed and 
prepared for voting by the five working groups in parallel breakout sessions. The level of 
evidence and strength of each recommendation proposed by the group was defined based on 
the ‘Infectious Diseases Society of America-United States Public Health Service Grading 
System’, as shown in Table 1 [12]. Recommendations from all working groups were then 
presented to the full expert panel for deliberation and amendment, as needed. Finally, a vote 
was carried out to establish the level of agreement among the expert panel. Members of the 
panel were given the opportunity to abstain from the voting process, to allow for cases where 
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they felt they did not have enough expertise in the area to agree or disagree, or if they had any 
conflict of interest which could influence their vote. 
Results from this consensus conference, including all agreed recommendations and a 
summary of evidence supporting each recommendation, are described in this article. A 
summary of all recommendations is included in supplementary Table S1, available at Annals 
of Oncology online.  
The draft manuscript was reviewed by two representatives of patient advocacy groups from 
France (Olivier Jerome, President of CERHOM, Villejuif, France) and Norway (Hans Sverre 
Hansen-Gaard, TGCCS, Oslo, Norway). The final manuscript was reviewed and approved by 
all ESMO consensus panel members. 
 
SECTION 3: RESULTS 
Diagnostic work-up and patient assessment 
5. Old and new biomarkers 
Assessment of the serum biomarkers α-fetoprotein (AFP), beta-human chorionic 
gonadotropin (β-hCG) and lactate dehydrogenase is a prerequisite for the staging of TGCC, 
monitoring of treatment outcomes and early detection of TGCC relapse [13, 14]. Drawbacks 
of these classical biomarkers include having a diagnostic sensitivity of only 60%–80% and a 
wide variation in marker expression levels in different histologic subgroups and clinical 
stages [15, 16]. Potential new biomarkers include the microRNAs miR-371-3 and miR-
302/367 cluster, which are present in TGCC tissue [17, 18] and are also known to circulate in 
serum [19, 20]. These microRNAs can be measured using the quantitative polymerase chain 
reaction method. Currently, results from four pilot studies have suggested that serum levels of 
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miR-302/367 and miR-371-3 are promising biomarkers of TGCC [19, 21-23]. More recently, 
a prospective study in Germany in 166 patients with TGCC and 106 healthy controls has 
indicated that mi-R371a-3p may be a highly useful marker, featuring a sensitivity of 86.3% 
(95% confidence interval [CI]: 79.7-90.4) and a specificity of 92.5% (95% CI: 89.0 -95.9) 
[24]. Serum levels of miR-371a-3p were significantly higher in patients with metastatic 
disease than in those with localised disease. In addition, serum levels of miR-371a-3p 
correlated with tumour size in stage I disease and decreased to normal after completion of 
treatment. Increasing serum levels of miR-371-3p were associated with treatment failure, and 
high levels were observed in patients with disease relapse. Importantly, teratoma and germ 
cell neoplasia in situ (GCNIS) do not appear to express these particular microRNAs, as 
shown in two recent studies [24, 25]. Thus, miR-371a-3p outperforms the classical 
biomarkers and represents a highly sensitive and specific new biomarker for TGCC. While 
this marker deserves attention by clinicians managing patients with TGCC, particularly given 
that a serum diagnostic test for miR-371a-3p is expected to be introduced soon into clinical 
practice [26], issues around laboratory standardisation and availability of the test must be 
resolved before this new biomarker can be recommended for routine clinical use. 
 
Post-chemotherapy surgery, salvage chemotherapy, salvage and 
desperation surgery, and special topics 
23. When is post-chemotherapy retroperitoneal lymph-node dissection (PC-RPLND) 
indicated? 
The most important consideration for post-chemotherapy surgery is whether a complete 
resection of residual radiological lesions is possible. Patients do not usually benefit from 
debulking or incomplete resections. Removal of the residual mass only (lumpectomy) is 
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associated with a risk of incomplete resections and should not be performed. Post-
chemotherapy surgery should therefore only be performed at high-volume centres with 
multidisciplinary teams who perform this procedure regularly. Patients with residual lesions 
after chemotherapy should be referred to these centres [27, 28].  
A bilateral open PC-RPLND remains the standard of care, based on mapping studies of nodal 
deposits and retrospective studies [29-33]. The field and extent of surgery should be based on 
the pre-chemotherapy pattern of metastases, and a nerve-sparing technique is recommended 
whenever possible. In patients presenting with infra-hilar nodal metastatic disease, the 
bilateral resection template, when indicated, should include infra-hilar, pre-caval and para-
caval nodes medial to the right ureter, and retro-caval, inter-aorto-caval, pre-aortic, retro-
aortic and para-aortic nodes medial to the left ureter, as well as the ipsilateral iliac nodes. In 
patients presenting with nodal metastatic disease outside the classical template, all sites 
outside the template should be included in the resection. This particularly applies to patients 
with supra-hilar and pelvic disease. 
A more limited dissection, defined as a ‘unilateral’ template, may be an alternative to a full 
bilateral resection. Eligible patients include those with resectable residual lesions <5 cm in 
the maximum axial diameter within the planned template, and those with residual 
retroperitoneal nodal disease within the pre-chemotherapy primary landing site of the 
tumour-bearing testis. [34-37]. Minimally-invasive laparoscopic RPLND should only be 
performed in high-volume, multidisciplinary testicular cancer centres with additional 
laparoscopic expertise. 
Adjunctive resections in addition to PC-RPLND are required in up to 20% of patients, and 
may include nephrectomy, vascular resection and/or other intra-abdominal visceral resections 
[38-40]. The aim of these procedures is complete resection of all residual disease. Where this 
does not appear feasible due to multi-focality or anatomical difficulty, incomplete resections 
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may not be beneficial. The combination of thoracic and retroperitoneal resections is relatively 
common. The timing and sequence of combined resections should be based on the location of 
the highest volume of residual disease [41]; usually, the first site of resection is in the 
retroperitoneum. The histology of residual disease in different organs may be discordant [42-
44]. Therefore, in the presence of resectable disease in the retroperitoneum and thorax, 
lesions in the thorax should also be resected. 
In patients with bilateral thoracic disease, the initial resection should be unilateral. A 
discordance rate of up to 20% has been reported [45]. Decisions for contralateral pulmonary 
resections are complex and should be based on the number of lesions, their size and location.  
Surgery for liver lesions may involve wedge resection or full lobectomy and may be 
performed at the time of RPLND or as a separate procedure [46, 47]. 
Patients with necrosis or complete resection of differentiated teratoma require no further 
treatment. The benefit of adjuvant treatment with two cycles of cisplatin-based chemotherapy 
in patients with an International Germ Cell Consensus Classification Group classification of 
‘intermediate risk’ or ‘poor risk’ at initial presentation, those with >10% viable tumour in the 
resection specimen, and/or in patients with incomplete resection, has recently been 
questioned as the value of complete resection of residual masses is more relevant for 
improving outcome than any adjuvant chemotherapy [48, 49].  
A small number of patients will experience radiological progression during chemotherapy 
despite tumour marker decline or normalisation (so called ‘growing teratoma’). If possible, 
chemotherapy should be completed as planned followed by resection of all radiological 
lesions [50]. Salvage chemotherapy is not indicated in patients with ‘growing teratoma’. 
Late relapses are defined as evidence of new lesions, or sequentially increasing serum tumour 
markers (AFP or HCG), more than 2 years after ≥3 cycles of cisplatin-based chemotherapy. 
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Viable cancer and/or somatic-type malignant transformation that do not respond well to 
chemotherapy are more frequent in late relapse than in early relapses [51-53]. Available 
evidence emphasises the central role of surgery in these patients [54, 55]. There is currently 
no evidence to show that chemotherapy, either before or after complete resection, improves 
the overall outcome. However, conventional-dose chemotherapy and high-dose 
chemotherapy have both been associated with long-term remissions in a small proportion of 
patients with unresectable late relapses [56, 57]. 
 
Survivorship and follow-up schemes 
26. How can post-therapeutic psychosocial issues be minimised, and HRQoL protected? 
HRQoL: emotional and psychosocial issues. 
Long term global HRQoL is similar between TGCCSs and the general population, regardless 
of the applied treatment [9]. However, chronic side effects, particularly after chemotherapy 
(including peripheral neuropathy, Raynaud’s syndrome, hearing loss and chronic fatigue 
[CF]), impact negatively on global, physical and mental HRQoL [10, 11]. 
Patients with a ‘helpless-hopeless’ coping style and limited social support experience poorer 
mental HRQoL, anxiety and depression [58]. In comparison with the general population, 
long-term TGCCSs express higher levels of anxiety; young age and certain socio-economic 
factors (including unemployment, low educational level and alcohol problems) can increase 
anxiety and stress, which in turn reduce HRQoL [59]. Some patients experience fear of 
recurrence in the long term, especially those with a medium educational level, traumatic 
cancer-related stress symptoms and neurotic personality [60]. Although there is currently no 
evidence of testicular cancer leading to subsequent unemployment or reduced work 
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engagement, poorer health and reduced work ability related to physical and psychological 
symptoms after cancer treatment is reported for a subgroup of patients [61, 62].  
Quality of life and post-therapeutic psychosocial issues. 
TGCCSs are more likely to have impaired sexuality (ejaculation and erectile disorders, 
reduced sexual interest and enjoyment) compared with healthy men of the same age [63-65]. 
Ejaculation impairment is usually caused by damage to sympathetic nerves after RPLND and 
may reduce sexual satisfaction [65]. Overall sexual problems are associated with older age, 
lack of a partner, high anxiety and change in body image [64, 65]. 
Self-reported cognitive complaints are common among TGCCSs and are linked with CF (i.e. 
fatigue above a certain level after a median observation time, as defined by the fatigue scale 
used) and emotional distress [66]. Recent studies have also identified objective cognitive 
impairments (mainly in verbal learning, memory and processing speed) after treatment, with 
younger age and a higher number of chemotherapy cycles associated with a greater incidence 
of overall decline in cognitive function [67, 68].  
Most patients with testicular cancer have at least one supportive care need, including physical 
care, lifestyle programme support, attitude towards self-management (including 
psychological support) and eHealth [69, 70]. Recent survivorship care plans among cancer 
survivors have generally not demonstrated improvements in HRQoL, satisfaction or distress 
[71]. Nevertheless, healthcare professionals should inform patients about the potential late 
negative effects of treatment, and endeavour to identify psychological distress early. A 
healthy lifestyle should always be promoted. Future research will examine the potential 
benefit of TGCCS-specific patient care plans. 
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27. How should fatigue be identified, prevented and treated?  
Chronic fatigue 
CF has been described as one of the most common and distressing adverse effects of cancer 
and its treatment [72]. CF should be regularly assessed using validated questionnaires [73]. 
Commonly used fatigue questionnaires include the Fatigue Questionnaire (FQ) [74], 
Functional Assessment of Cancer Therapy - Anaemia and Fatigue (FACT-An) [75] and the 
EORTC Quality of Life Questionnaire (QLQ C30) (fatigue subscale) [76]. [Note to Annals: 
The above abbreviations have been retained, despite only appearing once, since these are the 
known terms for these questionnaires and will likely be more recognisable to the reader than 
the terms written in full. Also, the term Anaemia is in UK spelling to align with journal style] 
CF (i.e. fatigue above a certain level after a median observation time as defined by the fatigue 
scale used) is more common in TGCCSs (16%) than in the general male population (10%) 
[77-79]. The prevalence of CF increases with age in the general male population, from 9.6% 
to 12.2% in the age cohorts 40–49 and 50–59 years, respectively [79], with a substantial 
increase in CF from 12 to 19 years after treatment combined with biochemical hypogonadism 
[80]. Moderate or high physical activity appears to have a preventive and therapeutic effect 
[80]. CF has been mitigated by cognitive behavioural therapy and mindfulness-based cancer 
recovery [81]. Healthcare professionals should strive to prevent CF through early detection of 
fatigue and lifestyle interventions throughout treatment and follow-up of co-morbid 
conditions. Testosterone substitution may be considered. CF may dramatically impair 
HRQoL and work ability, and the disturbing increase in CF among TGCCSs and its 
association with partly treatable side effects underlines the importance of continued long-
term assessments of TGCCSs.  
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28. How can the risk of ototoxicity and neurotoxicity be minimised? 
Ototoxicity. 
Ototoxicity and neurotoxicity are both important toxicities related to cisplatin treatment as 
well as ageing, and may substantially impair HRQoL [82]. After treatment of metastatic 
disease with standard-dose bleomycin/etoposide/cisplatin (BEP) regimens, 20%–25% of 
patients report long-term hearing impairment and tinnitus [83, 84]. When objectively 
measured by audiograms covering frequencies up to 12 kHz, and without any comparison 
with age-matched controls, only 20% of patients have normal audiograms [85]. However, 
daily life hearing ability is associated with findings on audiograms up to only 6–8 kHz [86]. 
The cumulative dose of cisplatin has consistently been shown to be a risk factor for 
ototoxicity, and scheduled administration with cisplatin 100 mg/m2 as 20 mg/m2/day over 
5 days, as opposed to 50 mg/m2/day over just 2 days, reduces the risk of hearing impairment 
and tinnitus [85, 87, 88]. Cisplatin-induced ototoxicity may become an increasing problem 
with increasing age-related hearing loss (premature presbycusis). Various genetic 
polymorphisms have been associated with an increased risk of ototoxicity [89-93], but these 
findings have not influenced clinical practice. Other possible risk factors include severe noise 
exposure prior to treatment, co-treatment with other ototoxic agents (such as 
aminoglycosides) and abnormal renal function [94, 95]. Drugs to prevent ototoxicity, or 
therapy to relieve symptoms, have not yet been identified.  
Neurotoxicity. 
Self-reported chemotherapy-induced peripheral sensory neuropathy (CIPN) has been reported 
in 5% of patients after one cycle of BEP [96], and in 25%–35% of patients with germ cell 
cancer treated with three to four cycles of BEP [87]. The risk of neuropathy increases with 
cumulative cisplatin doses exceeding 300 mg/m2, and almost every patient receiving doses 
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higher than 500–600 mg/m2 will experience neurotoxicity [97]. Although patient-reported 
symptoms are often partly reversible, not least due to patients’ adjustment to the problem 
(‘response shift’), they persist in 20%–25% of patients after 2 years of follow-up [83]. The 
risk of CIPN has been associated with polymorphisms in glutathione S-transferases and 
excision repair cross-complementation group 1 protein (ERCC1) [98-100], and long-term 
neurotoxicity has been associated with residual serum platinum levels [101]. However, these 
findings have not led to new management strategies. [Note to Annals/ESMO: ERCC1 
retained, despite only being mentioned once, as it is more commonly used than the 
description as written in full] 
Various neuroprotective therapies have been tested [102]. Vitamin E has shown some effect 
[103, 104] but results could not be replicated in larger studies [105]. Promising results were 
achieved with amifostine, but as this drug has acute side effects and may also reduce the 
anticancer potency of chemotherapy, it is not routinely used [106]. In one study, treatment 
with duloxetine was associated with positive effects on long-term CIPN; however, the 
majority of patients in this study were experiencing oxaliplatin-induced CIPN [107]. Other 
potentially therapeutic agents include tricyclic antidepressants and anticonvulsants [108].  
Thus, although symptomatic ototoxicity and neurotoxicity are currently unpreventable 
complications of cisplatin-based chemotherapy, they should generally not influence curative 
treatment. Nevertheless, patients should be informed about the risk of long-term ototoxicity 
and neurotoxicity prior to treatment. 
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29. Which TGCCSs should be offered testosterone replacement therapy? 
Leydig cell dysfunction and testosterone. 
Primary biochemical hypogonadism (low testosterone and high luteinising hormone [LH] 
levels) is prevalent in 5%–13% of patients after orchiectomy, increasing to 11%–27% after 
subsequent chemotherapy [109-112]. Furthermore, mean levels of LH are higher in 
chemotherapy-treated patients than in stage I patients after orchiectomy only, while mean 
testosterone levels are either comparable or decreased, suggesting compensated (high LH, 
normal testosterone) or uncompensated (high LH, low testosterone) chemotherapy-induced 
damage to Leydig cells [109-112]. 
Sprauten et al. demonstrated that TGCCSs had lower testosterone and higher LH and follicle-
stimulating hormone levels than healthy controls of a similar age at a median of 11 and 
18 years after orchiectomy [113]. Importantly, the proportion of biochemically hypogonadal 
TGCCSs seemed to increase between the 11-year follow-up and the 18-year follow-up [113].   
Symptoms of hypogonadism include decreased sexual function (often including loss of 
morning and spontaneous erections), a more sedate lifestyle and decreased bone health [114]. 
High body weight and the metabolic syndrome also seem to be related to testosterone levels 
in TGCCSs, but it is unclear whether obesity and the metabolic syndrome develop as a result 
of hypogonadism or vice versa [114]. 
Potential benefits of testosterone replacement therapy in young men with subclinical 
biochemical hypogonadism, or only mildly decreased testosterone levels, are uncertain. 
Howell et al. evaluated testosterone replacement in a randomised placebo-controlled trial 
among survivors of haematological malignancies with testosterone levels of <20 nmol/L (i.e. 
in the lower half of the normal range) [115]. They demonstrated a significant reduction in 
fatigue and low-density lipoprotein cholesterol, but no change in bone mineral density or 
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other lipids, in the testosterone replacement group compared with the placebo group. Studies 
of testosterone supplementation in TGCCSs are ongoing.  
In conclusion, the effect size of testosterone replacement in TGCCSs with low or low-to-
normal testosterone levels remains unclear. Whether the effects of testosterone replacement 
therapy are sustained during long-term use, and whether the beneficial effects outweigh any 
negative effects, are also unknown and warrant further investigation. It is also unclear if 
testosterone replacement therapy is a valuable treatment strategy in the management of 
obesity and the metabolic syndrome in TGCCSs. The current recommendation is that 
TGCCSs with repeatedly low testosterone levels and clinical symptoms of hypogonadism 
should be offered testosterone replacement therapy for a trial period of 3–6 months.  
 
30. How can the risk of cardiovascular disease (CVD) be reduced in TGCCSs? 
CVD, in particular coronary artery disease, is one of the most serious late effects after 
treatment for testicular cancer. Most studies have shown a 2–3-fold increase in risk for CVD 
in men previously treated with cisplatin-based chemotherapy or radiotherapy, compared with 
men treated with surgery only or the general population [116-118]. The risk is increased 
beyond ten years of follow-up, and risk prediction tools such as Framingham or SCORE, 
applied among all TGCCSs, have failed to identify high-risk individuals, likely due to their 
limited follow-up period (only 5 or 10 years) [119]. 
The absolute CVD risk 20 years after treatment is 6%–10%, with a particularly high risk 
(20%) after combined chemotherapy and radiotherapy [118]. The elevated risk of CVD in 
TGCCSs is thought to be primarily mediated by increases in CVD risk factors such as 
hypertension, obesity, hypercholesterolaemia, diabetes, smoking and physical inactivity 
[120]. The clustering of CVD risk factors into the metabolic syndrome [121] is a possible link 
131 
 
between cytotoxic treatment and later development of CVD [122]. Low testosterone levels, 
which are relatively common in TGCCSs, are related to increased risks for the metabolic 
syndrome and CVD [120]. In addition, platinum is detectable in serum up to 20 years after 
treatment [123], and circulating platinum may continuously damage the endothelium, 
resulting in an accelerated atherosclerotic process [124]. 
Healthcare providers should focus on the prevention of CVD from the start of cytotoxic 
treatment and throughout follow-up. Early and repeated counselling about the importance of 
a healthy lifestyle including smoking cessation, keeping a healthy diet and being physically 
active, play an important role in reducing the potential CVD risk among TGCCSs. Lifelong 
check-ups for CVD risk factors should be performed every 2 years, including measurements 
of blood pressure, weight, sex hormones, lipids and glucose [125]. Hypertension, 
hypercholesterolaemia, diabetes and hypogonadism should be treated. All patients with 
testicular cancer should have a survivorship care plan in place, including tools for acquiring 
and maintaining a healthy lifestyle.  
 
31. How can the risk of a second cancer and its consequences be reduced in TGCCSs? 
Second non-germ cell cancer. 
A significantly increased risk of a second cancer (relative risk ~1.5–2.1) represents one of the 
most feared long-term adverse effects after treatment for testicular cancer [126]. Before the 
introduction of cisplatin-based chemotherapy, most second cancers were localised below the 
diaphragm (pancreas, ventricle, bladder), within or close to the radiation fields [127, 128]. A 
significant dose-relationship has been demonstrated between the target radiation dose and 
incidence of a second cancer [129, 130]. The combination of radiotherapy and older 
chemotherapy regimens also increase the risk of a second cancer [131]. The increased risk of 
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a second solid malignancy becomes measurable 10–15 years after diagnosis and remains 
elevated for at least 35 years after initial treatment [131]. 
Following the gradual decline of radiotherapy as a treatment modality for testicular cancer 
since the mid-1970s, the pattern of second cancer development has changed. Leukaemia 
(mainly acute myeloid leukaemia) is most often diagnosed within the first 10 years after 
cisplatin-based chemotherapy and is associated with the cumulative dose of etoposide 
administered [132, 133]. The few published studies that have looked at the long-term 
incidence of solid tumours in patients treated with cisplatin-based chemotherapy indicate an 
increased risk of urological cancer and probably thyroid and lung cancer [128, 134]. 
However, larger studies are needed to clarify the risk of a second cancer in relation to 
treatment received for the primary testicular cancer. The prognosis of patients with post-
testicular cancer second non-germ cell cancers is similar to that of patients with the same 
non-germ cell cancers as their first lifetime malignancy [135].  
Second germ cell testicular cancer. 
Between 2% and 5% of patients with testicular cancer develop a germ cell tumour in the 
contralateral testicle, most frequently on the basis of GCNIS [136-138]. It is not clear 
whether early histological demonstration and treatment (most often radiotherapy) of this pre-
invasive stage is of overall clinical benefit for the individual patient [139].  
Four or more cycles of cisplatin-based chemotherapy delayed or prevented the development 
of an invasive testicular germ cell cancer, halving the rate at 5 years [140, 141].  
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Table S1. Summary of recommendations 
Guidelines statement LoE GoR Level of consensus 
1. Is there a role for targeted screening?    
1.1 Targeted screening should be advised for either a twin brother or those with 
two close family members with a history of germ cell tumours 
III-V A-C 97% (32) yes, 3% (1) no 
(33 voters) 
1.2 Since elevated testicular cancer risk exists for brothers and fathers, the patient 
should be encouraged to inform them of the need for self-examination 
III B 100% (33) yes 
(33 voters) 
2. Pathology assessments    
2.1 The pathology of testicular tumours should be assessed, or at least reviewed, by 
a specialist testicular pathologist who sees a minimum of 30 cases per year 
III A 87.1% (27) yes, 12.9% (4) abstain 
(31 voters) 
2.2 The WHO 2016 classification should be routinely adopted for testicular 
pathology assessment 
III A 74.2% (23) yes, 25.8% (8) abstain 
(31 voters) 
2.3 National or international minimum dataset guidelines should be used by 
testicular pathologists. The dataset for pathology reporting to minimum 
standards should be according to the ICCR minimum dataset 
III A 100% (31) yes 
(31 voters) 
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3. Should contralateral biopsy be performed?    
3.1 Biopsies of the contralateral testis at the time of orchiectomy should be 
discussed with, and recommended to, high-risk patients (i.e. those aged 
<40 years with a small atrophic testis and/or microlithiasis) 
III A 93.8% (30) yes, 3.1% (1) no, 3.1% 
(1) abstain (32 voters) 
4. Imaging techniques    
4.1 Testicular US using high frequency (>10 MHz) probe with colour Doppler 
assessment should be performed to confirm the presence of a testicular mass 
prior to orchiectomy or possible exploration of the contralateral testis 
V A No vote obtained 
4.2 Contrast-enhanced CT is recommended in all patients for staging prior to 
orchiectomy 
III A No vote obtained 
4.3 MRI may be helpful for characterisation of equivocal CT findings (e.g. in liver, 
bone, brain) 
IV A No vote obtained 
4.4 Brain MRI (or contrast-enhanced CT if MRI is contraindicated) is 
recommended in patients with symptoms or those with widespread metastatic 
disease and high levels of β-hCG 
IV A No vote obtained 
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4.5 MRI is not routinely recommended in all patients for staging of the 
retroperitoneum 
III B 94.1% (32) yes, 5.9% (2) abstain 
(34 voters) 
4.6 PET-CT is not routinely recommended in all patients for staging I B 94.1% (32) yes, 5.9% (2) abstain 
(34 voters) 
4.7 PET-CT is not considered to be useful for staging in the case of negative 
contrast-enhanced CT and marker-positive disease 
V C 88.2% (30) yes, 5.9% (2) no, 5.9% 
(2) abstain (34 voters) 
4.8 In marker-negative disease, if contrast-enhanced CT shows equivocal lymph 
nodes, repeated staging with contrast-enhanced CT after 6–8 weeks is 
recommended 
V B 97.1% (33) yes, 2.9% (1) abstain 
(34 voters) 
4.9 In marker-negative disease, if contrast-enhanced CT shows equivocal lymph 
nodes, repeated staging with PET-CT is not recommended  
V C 88.2% (30) yes, 5.9% (2) no, 5.9% 
(2) abstain (34 voters) 
4.10 An MRI can be recommended for follow-up of the retroperitoneum, if standard 
protocols are used and the results are reported by an experienced radiologist 
III A 85.3% (29) yes, 2.9% (1) no, 11.8% 
(4) abstain (34 voters) 
4.11 FDG-PET-CT may be helpful to assess residual masses >3 cm in patients with III B No vote obtained 
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seminoma if performed at least 8 weeks after the end of chemotherapy. If the 
results are negative, FDG-PET-CT has a very high negative predictive value 
4.12 Repeat FDG-PET-CT may be useful in patients with marker-positive relapse 
and a negative contrast-enhanced CT result 
IV B No vote obtained 
4.13 The follow-up contrast-enhanced CT should be of the abdomen only IV C 78.8% (26) yes, 9.1% (3) no, 12.1% 
(4) abstain (33 voters) 
5. Old and new biomarkers 
See Section 3 of supplementary text for recommendations 
   
6. Are there risk factors validated and/or accepted for seminoma?    
6.1 Both rete testis stromal invasion and primary tumour size should be considered 
as risk factors for relapse in stage I seminoma 
III B 91% (29) yes, 9% (3) abstain 
(32 voters) 
6.2 In patients with seminoma, in the case of primary tumour size, there is no 
definitive cut-off value; however, larger tumours appear to confer higher risk of 
recurrence as a continuous variable 
III B 94% (30) yes, 6% (2) abstain 
(32 voters) 
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6.3 Patients with seminoma without any identified risk factor (e.g. no rete testis 
involvement and small tumour size) have a very low risk of recurrence 
III B 75% (24) yes, 25% (8) abstain 
(32 voters) 
7. Are there risk factors validated and/or accepted for non-seminoma?    
7.1 In patients with non-seminoma, LVI is the key risk factor indicating disease 
relapse 
III B 100% (32) yes (32 voters) 
7.2 In patients with non-seminoma, a combination of LVI and predominance of EC 
appears to be associated with an even higher rate of stage II progression or 
relapse versus LVI alone 
III B 94% (30) yes, 6% (2) abstain 
(32 voters) 
7.3 Prospective collection of data on both markers (LVI and EC) is warranted III B 100% (32) yes (32 voters) 
8. Who should be offered adjuvant chemotherapy?     
8.1 Patients with seminoma and a low risk of relapse should not be offered 
adjuvant chemotherapy 
III C 91% (30) yes, 6% (2) no, 3% (1) 
abstain (33 voters) 
8.2 In patients with seminoma and a higher risk of relapse, surveillance or adjuvant 
carboplatin are options  
III C 91% (30) yes, 6% (2) no, 3% (1) 
abstain (33 voters) 
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8.3 In patients with seminoma, patient autonomy should be taken into account 
following thorough provision of information regarding the pros and cons of the 
alternative treatment strategies 
III C 91% (30) yes, 6% (2) no, 3% (1) 
abstain (33 voters) 
8.4 In patients with high-risk non-seminoma, adjuvant chemotherapy with one 
cycle of BEP is recommended if the patient is considered eligible for such 
treatment. Surveillance may be an alternative to adjuvant chemotherapy 
III B 72% (23) yes, 25% (8) no, 3% (1) 
abstain (32 voters) 
8.5 In patients with non-seminoma, patient autonomy should be taken into account 
following the provision of thorough information regarding the pros and cons of 
alternative management strategies 
III B 72% (23) yes, 25% (8) no, 3% (1) 
abstain (32 voters) 
8.6 In patients with low-risk non-seminoma who are eligible for adjuvant 
chemotherapy, surveillance is recommended. Adjuvant chemotherapy may be 
an alternative to surveillance 
III B 97% (32) yes, 3% (1) abstain 
(33 voters) 
8.7 In patients with low-risk non-seminoma, patient autonomy should be taken into 
account following the provision of thorough information regarding the pros and 
cons of the alternative management strategies 
III B 97% (32) yes, 3% (1) abstain 
(33 voters) 
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9. Should adjuvant chemotherapy be limited to one course of chemotherapy?    
9.1 One course of carboplatin AUC 7 is the standard adjuvant chemotherapy in 
stage I seminoma 
I B 97% (30) yes, 3% (1) abstain 
(31 voters) 
9.2 One course of adjuvant BEP is the standard adjuvant chemotherapy in stage I 
non-seminoma  
III B 97% (30) yes, 3% (1) abstain 
(31 voters) 
10. What is the optimal treatment of relapse after adjuvant chemotherapy?    
10.1 In patients with seminoma, treatment of relapse after adjuvant chemotherapy 
should be standard treatment according to the prognostic classification for 
metastatic disease 
III B 93% (28) yes, 7% (2) abstain 
(30 voters) 
10.2 In patients with non-seminoma, treatment of relapse after adjuvant 
chemotherapy should be standard chemotherapy for metastatic disease 
III B 90% (28) yes, 10% (3) abstain 
(31 voters) 
10.3 In patients with non-seminoma with localised abdominal and marker-negative 
relapse, NS-RPLND is the preferred option for primary salvage treatment 
III B 90% (28) yes, 10% (3) abstain 
(31 voters) 
11. Other treatment alternatives for stage I disease: is there a role for RPLND?     
156 
 
11.1 RPLND is an alternative treatment option to active surveillance or adjuvant 
chemotherapy in patients with stage I non-seminoma who are not eligible for or 
not willing to accept one of the above mentioned therapeutic options 
III B 90% (28) yes, 6% (2) no, 3% (1) 
abstain (31 voters) 
11.2 RPLND is the standard treatment in patients with clinical stage I pure teratoma 
and risk factors for occult retroperitoneal disease 
III B 62% (20) yes, 16% (5) no, 22% (7) 
abstain (32 voters) 
11.3 RPLND is the standard treatment in patients with clinical stage I teratoma with 
malignant somatic transformation 
III B 90% (28) yes, 3% (1) no, 6% (2) 
abstain (31 voters) 
12. Is there still a role for radiotherapy in clinical stage I testicular seminoma?    
12.1 Adjuvant radiation therapy is not recommended for clinical stage I seminoma 
except in exceptional cases 
I B 100% (25) yes (25 voters) 
13.  How should patients with stage IIA or IIB seminoma be treated?    
13.1 Evidence of metastatic disease has to be unequivocal in order to make a 
diagnosis of clinical stage IIA seminoma 
V A 91% (29) yes, 3% (1) no, 6% (2) 
abstain (32 voters) 
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13.2 Patients with clinical stage IIA seminoma can be treated with radiotherapy 
(30 Gy in 2 Gy fractions) or chemotherapy (three cycles of BEP or four cycles 
of EP) 
IV B 43% (12) chemotherapy, 32% (9) 
radiotherapy, 18% (5) no 
preference, 7% (2) abstain (28 
voters) 
13.3 Patients with clinical stage IIB seminoma should be treated with three cycles of 
BEP or four cycles of EP. Radiotherapy (36 Gy in 2 Gy fractions) should only 
be given in selected cases 
IV B 91% (31) yes, 3% (1) no, 6% (2) 
abstain (34 voters) 
14. Should different chemotherapy regimens be used in different clinical 
scenarios of metastatic seminoma? 
   
14.1 Three cycles of BEP is the recommended first-line chemotherapy for most good 
prognosis patients with metastatic seminoma. Four cycles of EP may be 
considered as an alternative 
II A 80% (24) yes, 10% (3) no, 10% (3) 
abstain (30 voters) 
14.2 Four cycles of EP should be considered as the alternative first-line 
chemotherapy for good prognosis patients with metastatic seminoma who are 
not suitable for bleomycin 
II A 100% (30) yes (30 voters) 
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14.3 Four cycles of BEP (or four cycles of VIP) should be considered in patients 
with intermediate prognosis seminoma. VIP is favoured in patients with 
contraindications to bleomycin 
III A 94% (29) yes, 6% (2) abstain (31 
voters) 
15. What is the optimal treatment for patients with clinical stage IIA and IIB 
non-seminoma with normal or normalised serum tumour markers after 
orchiectomy?  
   
15.1 All patients with clinical stage IIA NSGCT (evidence of enlarged 
retroperitoneal lymph nodes of <2 cm) and normal STMs should have 
metastatic disease confirmed (e.g. by biopsy or repeated imaging 8 weeks after 
surgery) 
III A No vote obtained 
15.2 The recommended treatment for confirmed clinical stage IIA non-seminoma 
with normal/normalised STMs is either BEP/EP ± NS-RPLND, or primary NS-
RPLND ± adjuvant chemotherapy. Discussion regarding the pros and cons of 
these options with the patient is recommended 
III A 45% (13) BEP/EP ± NS-RPLND; 
34% (10) NS-RPLND ± adjuvant 
chemotherapy; 7% (2) no 
preference, 14% (4) abstain (29 
voters) 
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15.3 The recommended treatment for clinical stage IIB non-seminoma with 
normal/normalised STMs is primary BEP/EP ± NS-RPLND 
III B 88% (29) BEP/EP ± NS-RPLND, 
3% (1) NS-RPLND ± adjuvant 
chemotherapy, 6% (2) no 
preference, 3% (1) abstain (33 
voters) 
16. How should intermediate prognosis metastatic non-seminoma be treated?    
16.1 The recommended treatment for intermediate prognosis metastatic NSGCT is 
four cycles of BEP or four cycles of VIP with G-CSF support in cases where 
bleomycin is contraindicated. Chemotherapy should be followed by resection 
of residual masses when present 
II A 89% (25) yes, 11% (3) abstain (28 
voters) 
17. In patients with poor-prognosis NSGCT, should chemotherapy be 
intensified upfront, be adjusted based on tumour marker decline, or be 
administered using standard dosing schedules? 
   
17.1 Tumour marker decline (i.e. using the GETUG risk calculator: 
https://www.gustaveroussy.fr/calculation-tumor/NSGCT.html) after one to two 
cycles of first-line cisplatin-based chemotherapy should be assessed to predict 
II B 68% (17) yes, 8% (2) no, 24% (6) 
abstain (25 voters) 
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outcomes in poor prognosis patients 
17.2 Tumour marker decline after one to two cycles of first-line cisplatin-based 
chemotherapy should be used to guide treatment in poor prognosis patients with 
inadequate decline 
II B 71% (17) yes, 17% (4) no, 12% (3) 
abstain (24 voters) 
17.3 Early treatment intensification (dose-intensified chemotherapy) should be 
considered in the event of inadequate tumour decline after one to two cycles of 
first-line cisplatin-based chemotherapy. However, four cycles of BEP remains 
standard in patients with a favourable tumour decline 
II C 65% (17) dose intensification in 
selected patients, 23% (6) four 
cycles of BEP, 12% (3) dose 
intensification in all patients 
(26 voters) 
18. How should we treat primary mediastinal NSGCT (localised and 
metastatic)? 
   
18.1 For patients with primary mediastinal NSGCT, treatment with chemotherapy 
regimens used for poor prognosis NSGCT are recommended. Post-
chemotherapy surgery is recommended for all patients irrespective of marker 
status. Bleomycin should either be closely monitored to prevent clinical lung 
III B 46% (12) chemotherapy, with 
intensification in case of 
unsatisfactory tumour marker 
decline, followed by surgery (if 
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toxicity or replaced by ifosfamide technically feasible), 23% (6) four 
cycles of BEP followed by surgery 
(if technically feasible), 19% (5) 
upfront intensified chemotherapy 
irrespective of tumour marker 
decline followed by surgery, 8% (2) 
four cycles of VIP followed by 
surgery (if technically feasible), 4% 
(1) primary surgery followed by 
chemotherapy (26 voters) 
19. What is the appropriate management for patients with upfront brain or 
bone metastases? 
   
19.1 Chemotherapy according to the IGCCCG classification for poor prognosis 
TGCC is recommended as standard of care for patients with upfront brain 
and/or bone metastases. Patients with upfront symptomatic or asymptomatic 
multiple brain metastases should commence systemic treatment before using 
III A 100% (24) yes (24 voters) 
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other (local) treatment modalities 
19.2 There are no high-quality data governing routine use of post-chemotherapy 
local treatment (surgery or radiation) for the brain or bone. Primary whole-
brain radiotherapy is not recommended 
IV C 100% (24) yes (24 voters) 
19.3 Patients with upfront brain metastases, single residual lesions after 
chemotherapy and normal or normalised tumour markers should be considered 
for additional surgery or stereotactic radiation 
V A 75% (18) additional surgery or 
stereotactic radiation, 25% (6) no 
further local treatment (24 voters) 
20.  Poor prognosis NSGCT: when can orchiectomy be postponed and when can 
initial chemotherapy be reduced? 
   
20.1 In patients with advanced metastatic TGCC and/or those with impeding organ 
failure, orchiectomy can be postponed until the completion of chemotherapy. 
However, removal of the tumour-bearing testicle is mandatory after termination 
of chemotherapy or in-between cycles (without postponing the next cycle) 
V B 88% (28) yes, 12% (4) abstain (32 
voters) 
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20.2 In patients with widespread lung metastases, pure choriocarcinoma and high 
hCG, 2–3 days of full dose cisplatin and etoposide are suggested, with 
continuation of chemotherapy when the patient has recovered (e.g. day 14) 
V B No vote obtained 
20.3 Patients with chronic kidney disease (stage II–III or GFR 50–
90 mL/min/1.73 m2) before treatment should have any hydronephrosis relieved 
to enable delivery of full-dose cisplatin-based chemotherapy with little risk of 
clinically relevant changes in GFR 
IV B 91% (30) yes, 9% (3) abstain 
(33 voters) 
20.4 In patients with a GFR of 30–50 mL/min/1.73 m2, carboplatin-based 
chemotherapy (or cisplatin-based chemotherapy in patients undergoing 
haemodialysis) are options. Bleomycin should be omitted 
V C No vote obtained 
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20.5 Regardless of the degree of renal function, patients with hydronephrosis 
(unilateral or bilateral) should be relieved with either stent or nephrostomy 
prior to chemotherapy 
V B 100% (33) yes (33 voters) 
20.6 Patients with poor renal function should not be routinely treated with 
carboplatin but should be referred to high-volume centres for evaluation 
V A 100% (32) yes (32 voters) 
21.  What is the optimal treatment of older patients with metastatic TGCCs?    
21.1 Comprehensive risk-benefit evaluation of older patients with TGCC should 
include assessment of co-morbidities and patient disease risk category 
IV B No vote obtained 
21.2 In the first-line setting, there is generally no reason not to administer standard 
chemotherapy according to the risk category. Primary G-CSF prophylaxis is 
recommended in these patients as the risk of neutropaenic sepsis is higher in 
older patients 
IV B No vote obtained 
21.3 Standard-dose chemotherapy may be the preferred choice in most elderly 
patients, although limited safety data are available. Referral to an experienced 
IV B No vote obtained 
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centre is strongly recommended to help make treatment decisions 
22.  Should care of patients with metastatic TGCC be centralised?    
22.1 Besides orchiectomy, treatment of patients with TGCC should be conducted in 
high-volume centres 
IV A 77% (20) agree for all patients; 
23% (6) agree only for patients 
with metastases (26 voters) 
23.  When is PC-RPLND indicated?    
23.1 PC-RPLND is indicated in patients with non-seminoma and residual 
retroperitoneal lesions ≥1 cm in size 
IV A 89.3% (25) yes, 10.7% (3) no, 0% 
(0) abstain (28 voters) 
23.2 Indication for PC-RPLND should be determined based on the largest axial 
dimension of residual retroperitoneal lesions on CT scan in the presence of 
normal markers 
IV A 100% (28) yes (28 voters) 
24.  Salvage therapy    
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24.1 In patients with disease relapse, immediate surgery without prior biopsy should 
only be considered for:  
• non-seminoma patients relapsing with localised resectable lesions and 
negative STMs, as lesions may be due to enlarging teratoma without 
malignant components 
• late relapses in both seminoma and non-seminoma, because of a high 
incidence of chemotherapy-refractory disease 
V A 76.5% (26) yes, 5.9% (2) no, 17.6% 
(6) abstain (34 voters) 
24.2 In all other patients, particularly those with increasing STMs, surgery should be 
postponed until completion of salvage chemotherapy, even in the presence of 
resectable lesions  
III A 87.5% (28) yes, 12.5% (4) abstain 
(32 voters) 
25.  Salvage treatment for patients with brain metastases    
25.1 Surgery as well as stereotactic radiation with or without chemotherapy may be 
considered for patients with isolated brain relapse without evidence of systemic 
disease. When radiotherapy is considered, stereotactic radiation should be used 
rather than whole brain radiation whenever technically feasible 
V B 53.3% (16) yes, 26.7% (8) no, 
20.0% (6) abstain (32 voters) 
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26.  How can post-therapeutic psychosocial issues be minimised, and HRQoL 
protected? 
   
26.1 Patients should be informed of the potential long-term toxicities of treatment 
(i.e. ototoxicity and neurotoxicity, second cancers and CVD, as well as sexual 
difficulties, fatigue and cognitive dysfunction) 
III/IV B 97% (32) yes, 3% (1) abstain 
(33 voters) 
26.2 Patients should be reassured that in most cases, long-term overall HRQoL is 
similar to that in men who have not undergone treatment for testicular cancer 
IV B 97% (32) yes, 3% (1) abstain 
(33 voters) 
26.3 Vulnerable patients (e.g. those with psychological distress and poor social 
support) should be identified early to assess the need for support by social 
workers and psychological assistance 
IV B 97% (32) yes, 3% (1) abstain 
(33 voters) 
26.4 Physical activity and a healthy lifestyle should be recommended to all patients IV B 97% (32) yes, 3% (1) abstain 
(33 voters) 
27. How should fatigue be identified, prevented and treated?     
168 
 
27.1 In order to prevent fatigue, overtreatment should be avoided (i.e. by adherence 
to treatment guidelines) 
V B 100% (33) yes (33 voters) 
27.2 Fatigue should be addressed and documented during follow-up V B 100% (33) yes (33 voters) 
27.3 Contributing conditions should be identified and treated V B 100% (33) yes (33 voters) 
27.4 Personalised physical training should be recommended  IV B 100% (33) yes (33 voters) 
27.5 Referral for CBT should be considered IV B 100% (33) yes (33 voters) 
28.  How can the risk of ototoxicity and neurotoxicity be minimised?    
28.1 Symptomatic ototoxicity and neurotoxicity are unpreventable complications of 
cisplatin-based chemotherapy and should generally not influence treatment 
intensity 
III B 100% (33) yes (33 voters) 
28.2 Patients should be informed about the risk of ototoxicity and neurotoxicity 
before receiving cisplatin-based chemotherapy 
IV B 100% (33) yes (33 voters) 
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28.3 Further risk factors for ototoxicity and neurotoxicity should be avoided (e.g. 
aminoglycosides within weeks of chemotherapy, exposure to loud noises, 
smoking and poorly regulated diabetes) 
IV B 100% (33) yes (33 voters) 
29.  Which TGCCSs should be offered testosterone replacement therapy?    
29.1 Asymptomatic TGCCSs with testosterone levels below the normal range should 
not routinely be offered testosterone replacement therapy 
V C 74% (20) yes, 19% (5) no, 7% (2) 
abstain (27 voters) 
29.2 TGCCSs with testosterone levels below the normal range and clinical 
symptoms* should be offered testosterone replacement therapy 
V B 100% (33) yes (33 voters) 
29.3 TGCCSs with low testosterone levels and clinical symptoms* which resolve 
after short-term (3-6 months) testosterone substitution should continue 
testosterone replacement therapy  
V B 94% (30) yes, 6% (2) abstain 
(32 voters) 
29.4 TGCCSs with normal testosterone levels and clinical symptoms* which resolve 
after short-term (3-6 months) testosterone substitution should not continue 
testosterone replacement therapy 
V C 44% (11) yes, 12% (3) no, 44% 
(11) abstain (25 voters) 
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30.  How can the risk of CVD be reduced in TGCCSs?    
30.1 In order to reduce the risk of CVD, overtreatment should be avoided, especially 
the combination of chemotherapy and radiotherapy 
IV B 100% (33) yes (33 voters) 
30.2 Patients should receive repeated counselling about the importance of a healthy 
lifestyle in preventing CVD 
IV B 100% (33) yes (33 voters) 
30.3 Patients should receive regular check-ups to prevent CVD, including 
measurements of blood pressure, weight, sex hormones, lipids and glucose 
IV B 100% (33) yes (33 voters) 
30.4 Patients should receive treatment for hypertension, hypercholesterolaemia and 
diabetes to prevent CVD 
IV B 100% (33) yes (33 voters) 
31.  How can the risk of second non-germ cell cancer and its consequences be 
reduced in TGCCSs? 
   
31.1 TGCCSs who receive treatment in addition to orchiectomy should be informed 
about the risk of second cancers and the importance of contacting their 
healthcare provider if suspicious symptoms arise 
V B 94% (31) yes, 6% (2) no (33 voters) 
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31.2 TGCCSs should receive lifestyle counselling and be encouraged not to smoke V B 94% (31) yes, 6% (2) no (33 voters) 
32.  How should follow-up schedules be planned?    
32.1 When considering the risks of relapse depending on diagnosis and initial 
treatment, all seminoma stage I patients should be grouped together 
IV B 88% (29) yes, 6% (2) no, 6% (2) 
abstain (33 voters) 
Recommendations for minimal follow-up for seminoma stage I on active 
surveillance, non-seminoma stage I on active surveillance and after adjuvant 
treatment or complete remission for advanced disease are summarised in Tables 4–6 
   
33.  Suggested patient care plan to be provided to the patient and general 
practitioner at termination of uro-oncological follow-up 
A suggested survivorship care plan is provided in Table S5 
   
*Clinical symptoms: decreased sexual function (often including loss of morning and spontaneous erection), less active and more sedate lifestyle. 
AUC, area under the curve; BEP, bleomycin/etoposide/cisplatin; CBT, cognitive behavioural therapy; CT, computed tomography; CVD, 
cardiovascular disease; EC, embryonal carcinoma; EP, etoposide/cisplatin; FDG, fludeoxyglucose; G-CSF, granulocyte colony-stimulating 
factor; GFR, glomerular filtration rate; GoR, grade of recommendation; hCG, human chorionic gonadotropin; HRQoL, health-related quality of 
life; ICCR, International Collaboration on Cancer Reporting; IGCCCG, International Germ Cell Cancer Collaborative Group; LoE, level of 
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evidence; LVI, lymphovascular invasion; MRI, magnetic resonance imaging; NS, nerve-sparing; NSGCT, non-seminomatous germ cell tumour; 
PC, post-chemotherapy; RPLND, retroperitoneal lymph node dissection; PET, positron emission tomography; STM, serum tumour marker; 
TGCC, testicular germ cell cancer; TGCCS, testicular germ cell cancer survivor; US, ultrasound; VIP, vinblastine/ifosfamide/cisplatin; WHO, 
World Health Organization. 
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Table S2. Treatment options for stage IIA and IIB non-seminoma 
Treatment Characteristic 
Pros Cons 
BEP x 3 ± RPLND • No peri-operative 
morbidity in 75% of 
patients with a CR 
• Two therapies needed 
in 25% of patients 
• Side effects of 
chemotherapy seen in 
100% of patients 
• Risk of relapse 5%–
10% if no RPLND 
(including growing 
teratoma and GTS) 
RPLND without adjuvant 
chemotherapy 
• Histological 
confirmation 
• Immediate 
chemotherapy avoided 
• Serious side effects of 
RPLND (Clavien-
Dindo grade IIIB-V) 
in up to 5% of patients 
• 25% relapse rate in 
pathologic stage IIA 
• Up to 50% relapses in 
pathological stage IIB 
patients 
• Close follow-up 
needed 
174 
 
 
 
  
RPLND + adjuvant EP or 
BEP x 2 
• Histological 
confirmation of stage 
(25% pathological 
stage I with no need 
for adjuvant 
chemotherapy) 
• Low risk of relapse 
(1%–4%) 
• Serious side effects of 
RPLND (Clavien-
Dindo grade IIIB-V) 
in up to 5% of patients  
• Side effects of 
chemotherapy in 
100% of confirmed 
pathological stage II 
patients 
BEP, bleomycin/etoposide/cisplatin; CR, complete response; EP, etoposide/cisplatin; GTS, 
growing teratoma syndrome; RPLND, retroperitoneal lymph node dissection. 
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Table S3. Criteria and projected outcomes for patients with intermediate prognosis 
testicular cancer 
Non-seminoma (28% of cases) Criteria: 
5-year PFS 75% 
5-year survival 80% 
Testis/retroperitoneal primary 
No non-pulmonary visceral metastases 
AFP 1000–10 000 ng/mL or 
hCG 5000–50 000 IU/L or 
LDH 1.5–10 x ULN 
Seminoma (10% of cases) All of the following criteria: 
5-year PFS 67% 
5-year survival 72% 
 
Any primary site 
Non-pulmonary visceral metastases 
Normal AFP 
Any hCG 
Any LDH 
AFP, α-fetoprotein; hCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; 
PFS, progression-free survival; ULN, upper limit of normal. 
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Table 4. Relapsed GCC: International Prognostic Factors Study Group classification [1] 
Parameter Score points 
0 1 2 3 
Primary site Gonadal Extragonadal - Mediastinal 
non-seminoma 
Prior response CR/PRm- PRm+/SD PD - 
PFI, months >3 ≤3 - - 
AFP salvage Normal ≤1000 >1000 - 
hCG salvage ≤1000 >1000 - - 
Score sum (values from 0 to 10) 
Regroup score sum into categories: (0) = 0; (1 or 2) = 1; (3 or 4) = 2; (5 or more) = 3 
Add histology score points: pure seminoma = -1; non-seminoma or mixed tumours = 0 
Final prognosis score (-1 = very low risk; 0 = low risk; 1 = intermediate risk; 2 = high risk; 
3 = very high risk) 
AFP, α-fetoprotein; CR, complete remission; GCC, germ cell cancer; hCG, human chorionic 
gonadotrophin; PD, progressive disease; PFI, progression-free interval; PRm-, partial 
remission, negative markers; PRm+, partial remission, positive markers; SD, stable disease. 
Reprinted from [1] with permission. ©2010 American Society of Clinical Oncology.  All 
rights reserved. 
REFERENCE 
1. Lorch A, Beyer J, Bascoul-Mollevi C et al. Prognostic factors in patients with 
metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line 
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Table S5. Suggested survivorship care plan 
You were operated in the year _______ for testicular cancer, subtype:  
 Seminoma   Non-seminoma 
 No dissemination of disease was confirmed 
 Dissemination of disease was confirmed to ______________________________ 
Additional treatment 
 No 
 Chemotherapy (number of cycles: ______) 
 Radiotherapy 
 Surgery in addition to removal of the testicle: ______________________________ 
Date for last follow-up: ____________________ Hospital: _____________________ 
Responsible doctor: ______________________ Telephone: ___________________ 
You have completed the last oncological follow-up after previous treatment for testicular 
cancer. The risk for relapse of the disease is very low, and you will be taken care of by your 
general practitioner in the future. This patient care plan should be shown in case of future 
contact with the health services.  
You are at risk of a new tumour in the remaining testicle and regular self-examinations are 
important. Furthermore, another cancer type may develop after treatment with chemotherapy 
and/or radiotherapy. Some side effects from testicular cancer treatment may emerge several 
years after treatment (e.g. sub-normal values of the male sex hormone[testosterone]). In 
addition, men previously treated with chemotherapy and/or radiotherapy have an increased 
risk of hypertension, being overweight, elevated cholesterol levels and cardiovascular 
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disease. Thus, it is advisable to exercise regularly, refrain from smoking and avoid becoming 
overweight.  
We recommend that the following are monitored by the general practitioner: 
1) Blood pressure, height, weight, waist circumference 
2) Blood samples including fasting lipids (total cholesterol, HDL-cholesterol and LDL-
cholesterol, triglycerides), fasting glucose and hormones (testosterone, FSH and LH) 
3) Clinical examination if symptoms arise 
The purpose of these tests is to prevent, identify and possibly treat risk factors which might 
lead to complications (e.g. cardiovascular disease). We recommend tests every 2-3 years. If 
abnormal values are detected, further follow-up will be initiated by the general practitioner. 
FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; LH, luteinising hormone. 
 
 
 
